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Abstract
Cells have the ability to adapt in response to environmental stressors by
regulating RNA stability. Terminal uridylyltransferases (TUTases) have emerged
as essential enzymes in post-transcriptional regulation. TUTases catalyze the
untemplated addition of uridine residues to the RNA 3’-end, which generally leads
to RNA degradation. Human TUTase 4 (TUT4) regulates mRNA and miRNA
stability by initiating the decay of RNA through the addition of a poly(U) tail. TUT4
encodes two catalytic regions. Previously, the C-terminal catalytic motif was
thought to execute uridylation activity, while the N-terminal motif was thought to
be catalytically inactive. I here demonstrate that while less active than its Cterminal counterpart, the N-terminal motif is indeed capable of post-transcriptional
RNA editing and displays RNA substrate specificity. I further identified one of the
three catalytic aspartates required for uridylation activity. This reveals a
previously unknown catalytic function of the N-terminal catalytic domains with
implications for its biological function.

Keywords: TUT4, Uridylyltransferase, Nucleotidyltransferase, Non-canonical
poly(A) polymerase, TUT4 N-terminal catalytic region, uridylation, posttranscriptional modification, RNA regulation, RNA decay, miRNA
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Chapter 1: Introduction
1.1 The flow of information through the central dogma
In 1958, Francis Crick explained a two-step process of the movement of
genetic information from deoxyribonucleic acids (DNA) to essential protein
products, which is termed the central dogma of molecular biology (Figure 1)1.
DNA, a double-stranded helix, stores our genetic information in specific
nucleotide sequences, dictating which proteins will ultimately be expressed. The
first step in the central dogma is the transcription of DNA. Ribonucleic acid (RNA)
polymerase (Pol), an essential protein in this process, begins transcription by
binding to the DNA sequence. Pol II, specifically, is responsible for replication of
the genes involved in protein expression, forming messenger RNA (mRNA)2.
The binding of the Pol II complex results in the separation of the two nucleotide
strands, which is termed the ‘transcription bubble’2. Nucleoside triphosphates
(NTP) are required for this process, as complementary nucleotides are added to
the DNA template to form the RNA chain2. Transcription terminates when the
mRNA sequence is complete.
During the second step of the central dogma, the newly synthesized
mRNA is exported out of the nucleus and is used as a template for the
expression of proteins in the process of translation. In eukaryotes, the 80S
ribosome, a ribosome capable of elongation, binds to the mRNA 5’-untranslated
region (UTR) to initiate translation3, 4, 5. The 80S ribosome complex is formed in
two steps. The methionyl transfer RNA (Met-tRNA) is bound to the 40S subunit of

1

the ribosome in a complex with eukaryotic initiation factors (eIF) before being
recruited to the start codon of the mRNA3, 4, 5, 6, 7. The 60S ribosomal subunit
then joins the mRNA-bound complex forming the final 80S initiation ribosome3, 4,
5

. The ribosome moves down the mRNA in the 5’-3’ direction adding the correct

amino acid to the codon sequence.
Although the originally proposed central dogma seemed like a straight
forward process, over the years many different enzymes have been discovered
that are essential in regulating this process. Disruption at any level can result in
error and mutations during either transcription or translation. As a means of
survival, the cell has the ability to adapt to environmental stressors8. At the RNA
post-transcriptional level, many different mechanisms of regulation are involved in
making sure that RNA is tightly controlled. The addition of untemplated
nucleotides to the 3’-end of RNA is an important post-transcriptional modification
directly controlling RNA stability and therefore the amount of protein expressed8.
The addition of nucleotides is catalyzed by enzymes termed
nucleotidyltransferases. The most well-studied nucleotidyltransferases are
poly(A) polymerases (PAPs), which utilize adenosine triphosphate (ATP) to
modify RNA.

2

Nucleus
Cytoplasm
DNA
transcription

RNA

translation

Protein

Figure 1. The central dogma. The flow of information from DNA to protein as
proposed by Francis Crick in 1958. Double-stranded DNA undergoes
transcription, the copying of genetic data, into single-stranded mRNA. mRNA is
exported out of the nucleus before translation begins. This process translates the
mRNA genetic information into protein products.
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1.2 Poly(A) polymerases are essential enzymes for RNA regulation
Since the discovery of poly(A) tails on mRNAs in 19709, 10, PAPs have
been well studied for their roles in the maturation process and stability of
mRNA11, 12, 13 . PAPs, a member of the DNA polymerase b-like (polb) family,
modify mRNA by the untemplated addition of adenosine residues to the 3’-end12,
13

. In eukaryotes, canonical PAPs begin the poly(A) addition initially in the

nucleus, following pre-mRNA cleavage, as part of the mRNA maturation process,
ceasing transcription and stimulating mRNA export into the cytoplasm8, 13, 14, 15,
16

. The length of the poly(A) tail of mRNAs is an essential regulatory mode, where

varying lengths of the poly(A) tail determines life span and stability of the
mRNA17. Long poly(A) tails are important in mRNA stabilization and increase the
mRNA life span17. Polyadenylation of nuclear mRNA occurs when the cleavage
and polyadenylation specificity factor (CPSF) is recruited to a conserved
AAUAAA polyadenylation signal (PAS) on the mRNA17, 18, 19, 20, 21; This in turn
allows the nuclear poly(A) binding protein (PABPN1) to bind to the mRNA, which
promotes the addition of a long 3’-poly(A) tail by PAP21, 22 . In mammalian cells,
for example, the stabilizing poly(A) tail length is approximately 250 nucleotides
(nts) in length, while in yeast, the poly(A) tail can be up to 80 nts in length11, 17, 21,
22

. Once the 3’-end tail is shortened to less than 25 nts, due to each subsequent

RNA translation event, the proteins involved in mRNA stabilization and mRNA
translation can no longer bind17, 22, 23, 24. The shortening of the poly(A) tail results
in mRNA degradation.

4

Non-canonical PAPs (ncPAPs), which function in both the nucleus and
cytoplasm, have been more recently identified25, 26, 27. In the cytoplasm,
polyadenylation elongates the pre-existing mRNA poly(A) tail, allowing the PABP
to bind, forming a closed-loop and starting the process of translation16, 28.
Cytoplasmic mRNA poly(A) tail length is regulated carefully through both the
deadenylation and polyadenylation processes to either shut down or increase
translation, respectively16.

1.2.1 Molecular basis of nucleotide addition
On a molecular basis, both canonical and non-canonical PAPs catalyze
nucleotide addition via a conserved carboxylate triad, composed of three
aspartate residues26. In canonical PAPs, this triad is located in the N-terminal
catalytic domain13. In ncPAPs, the catalytic triad is located within a
nucleotidyltransferase (Ntr) domain8, 29. This aspartate triad functions to
coordinate two essential metal ions in the active site13. The first two aspartates
coordinate a single magnesium (Mg2+) ion, required for stability of the NTP
through interactions with the β- and γ-phosphates of the triphosphate moiety30, 31,
32

. The phosphates of the incoming nucleotide are also stabilized by interactions

with surrounding water molecules30, 32. The third aspartate coordinates the
second Mg2+ ion for the transfer of the nucleotide onto the RNA substrate by
weakening the attraction of the RNA 3’-hydroxyl to the hydrogen31. The 3’hydroxyl on the nucleotide residue in the -1 position of the RNA substrate is in
close proximity to the α-phosphate of the NTP, allowing for nucleophilic attack of
the α-phosphate12, and the subsequent formation of the phosphodiester bond,
5

releasing diphosphate. Figure 2 shows the addition of uridine triphosphate (UTP)
onto an RNA 3’-end.

6

Figure 2. Catalytic aspartate triad allows for the transfer of nucleotides onto
the RNA 3’-end. Aspartate 1 and 2 (Asp 1 and Asp 2) coordinate a Mg2+ ion
(purple) to stabilize the β- and γ-phosphate of the uridine triphosphate (UTP)
moiety. Aspartate 3 (Asp 3) lowers the RNA 3’-hydroxyl group affinity for
hydrogen, allowing for nucleophilic attack on the UTP α-phosphate. Water
molecule interactions not shown.

7

1.2.2 The discovery of RNA uridylation
The addition of U-residues on RNA has been known since the 1950s, but
with little implication to how important this RNA modification is33. It wasn’t until
shortly after poly(A) tails were discovered9, 10 that interest in poly(U) tails
increased, and the existence of poly(U) tails on both nuclear and cytoplasmic
RNA were detected8, 34. The addition of uridine residues to RNA was found to be
important in mitochondrial RNA editing of kinetoplastids35 , guide RNA (gRNA)
processing36, and the generation of mRNA. It wasn’t until the last 15 years that
uridylation on mRNA was discovered as a post-cleavage modification during
mRNA maturation37.
In recent years, ncPAPs which utilize nucleotides other than ATP to modify
RNA were identified. These ncPAPs, termed terminal uridylyltransferases
(TUTases) or poly(U) polymerases (PUPs), add UTP rather than ATP to the RNA
3’-end as a means of regulating RNA stability. Many terminal
nucleotidyltransferase (TNTase) homologs have been biochemically
characterized and are categorized into PAPs or TUTases (Table 1), yet the
nucleotide preference of some homologs remain uncharacterized8.

1.2.3 Adenylation vs uridylation in RNA stability
Adenylation has long been known as a mechanism to stabilize mRNA.
Monoadenylation by the ncPAP germline-development 2 (Gld2) has been
recently found to stabilize microRNA (miRNA)38. In contrast, recent studies found
that polyuridylation marks RNAs for degradation. RNA degradation following
polyuridylation has been found in mRNAs, histone mRNAs, and precursor
8

miRNAs (pre-miRNAs)27, 39, 40, 41. Interestingly, monouridylation of pre-miRNAs is
important in miRNA biogenesis42. The modification of a poly(A) or poly(U) tail
dictates the fate of the RNA (Figure 3). UTP specificity of TUTases is due to the
presence of a specific histidine residue, important for nucleotide recognition. In
2012, Bradley Lunde and colleagues discovered that histidine residue 336 (H336)
in the yeast ncPAP caffeine induced death protein 1 (Cid1) allowed for
preferential selectivity of UTP over ATP, which is conserved only in members of
the Cid1 family that have confirmed activity with UTP30. When H336 was mutated
to an asparagine residue, Cid1 preference for ATP increased, with a slight
decrease in UTP activity, confirming the importance of the histidine residue in
UTP selectivity30. More recently, Christina Z. Chung in our lab has shown that in
the ncPAP Gld2, which functions with ATP, nucleotide specificity can be changed
with the insertion of a histidine residue, in a position relative to H336 in Cid143.
This histidine insertion in the Gld2 sequence displayed activity with UTP over
ATP, with a significant decrease in ATP activity43. Sequence alignment of several
nucleotidyltransferases showed that this histidine residue is conserved in
uridylyltransferases, while adenylyltransferases have a different amino acid in the
homologous position or lack this amino acid altogether30, 43.
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Table 1. Over the past two decades, the different terminal nucleotidyltransferase
(TNTase) homologs have been associated with adenylation or uridylation activity
on various RNA substrates. Adapted from Chung, Seidl et al. 20178.

H. sapiens Tut1

Adenylation

Uridylation

mRNA
• NQ01, HO144, 45,

miRNA
• Multiple50
• miR-24, miR-29a

46, 47, 48, 49

51

U6 snRNA52, 53, 54
H. sapiens Tut2/
Papd4/Gld2

mRNA
• Multiple55, 56, 57, 58
• p5359
miRNA
• miR-12238, 60, 61
• miR-13438
• let-7a38, 62
• pre-let-7a62

miRNA
• pre-let-7a43
• miR-12238
• Group II premiRNA42, 63
• pre-miRNA with
5’-overhang64

H. sapiens Tut4/
Zcchc11

mRNA65
miRNA66, 67, 68
• multiple68
• Group II premiRNA42, 64
• pre-miRNA with
5’-overhang64
histone mRNA69

H. sapiens Tut7/Zcchc6

mRNA65
miRNA
• multiple68
• Group II premiRNA42
• pre-miRNA with
5’-overhang64
histone mRNA70

S. pombe Cid1

multiple mRNA25

10

multiple mRNA16, 39

Figure 3. Overview of mRNA modifications by adenylation and uridylation
in humans. Polyadenylation of A) mRNAs by Gld2 and B) pre-mRNA by TUT1
extends their half-life. C) TUT4 or TUT7 uridylation of histone mRNAs leads to 5’3’ and 3’-5’ degradation. D) TUT4 or TUT7 uridylation of mRNAs with short
poly(A) tails leads to 5’-3’ and 3’-5’ degradation. Adapted from Chung, Seidl et al.
20178.
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1.2.4 PAPs and TUTases belong to the same phylogenetic family
As outlined above, uridylation and adenylation have opposing effect on
RNA stability. Surprisingly, a phylogenetic analysis of over 300 members of the
polb superfamily showed that the enzymes are closely related, and
uridylyltransferase activity arose from adenylyltransferases multiple times during
evolution (Figure 4). Both TUTases and PAPs catalyze nucleotide addition using
the same two metal-ion coordinating mechanism. The two catalytically similar
reactions of adenylation and uridylation have opposing biological effects on RNA
stability: adenylation stabilizes mature miRNA or mRNA while uridylation
destabilizes or silences. We found it striking that TUTase activity appears to
emerge from a PAP ancestor at least 4 times independently in the evolution of
this TNTase family (Figure 4). We showed that a single amino acid change is
sufficient to convert an ATP adding enzyme into a UTP adding enzyme43. The
crystal structure of U-specific Cid1 revealed the molecular basis of nucleotide
discrimination: a single inserted histidine residue in TUTases sterically hinders
ATP from entering the active site30. It is possible that these enzymes diverged
from each other due to the need to regulate the same RNA substrates in an
opposing manner for different biological effects. We speculate that the gene
duplication events may have been related to the cells’ need to regulate the same
RNA substrates in a diametrically opposing manner. This enabled evolution of an
“off” switch, where uridylation signals decay, from an “on” switch, where
adenylation increases RNA stability (Figure 4).

12

Figure 4. Phylogenetic tree of TNTases. This figure was adapted from Chung,
Seidl et al. 20178. TUTase activity emerged from PAP activity in at least three
separate incidences. TUTases are marked in green, and PAP homologs in
purple.
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1.3 Terminal uridylyltransferases
Since their discovery, TUTases have gained interest in the scientific world
due to their ability to add uridine residues to the RNA 3’-end. Originally
discovered as a PAP in Schizosaccharomyces pombe (S. pombe), Cid1 was later
identified through biochemical characterization as the first TUTase, with the
ability to utilize UTP to modify RNA in yeast16. This novel discovery triggered an
investigation of human homologs, which were previously thought to function as
adenylyltransferases in vivo. Indeed, several human homologs are now known to
add uridine instead of adenine residues to modify different types of RNA,
including miRNA, mRNA, and small nuclear RNA (snRNA)24, 52, 66, 71.
While all TUTases modify their own specific substrates, the members of
the TUTase family have structural similarities. Cid1 consists of the catalytic core
of a nucleotidyltransferase (Ntr) domain and poly(A) polymerase (PAP) domain,
much like the human adenylyltransferase counterpart Gld216, 43. This catalytic
core is also found in terminal uridylyltransferase 4 (TUT4) and terminal
uridylyltransferase 7 (TUT7), which are part of the polb superfamily (Figure 5).
While Cid1, TUT4, and TUT7 have been shown to act as TUTases in vivo16, 39, 66,
67, 68, 69, 72, 73, 74

, Gld2 is a bona fide PAP38, 43, 59, 61, 75, 76 (Figure 5).

The ncPAP Gld2 is capable of adenylation of mRNA and miRNA, as well
as uridylation of miRNA38, 43, 57. In general, mRNA and miRNA adenylation by
Gld2 is important for stabilization38, while monouridylation of pre-miRNA by Gld2
has been implicated as part of the miRNA maturation process42. The yeast
homolog Cid1, shortly after its discovery as a TUTase in S. pombe, was found to
14

be crucial in the degradation of mRNA through polyuridylation39, 77. The poly(U)
tail addition catalyzed by Cid1 is important in a 5’-3’ degradation pathway in
yeast39. As the first discovered TUTase, this pathway in yeast was believed to be
conserved in other eukaryotes39, 77.
TUT1, a nuclear TUTase, is important in the stabilization of the U6
snRNA78. 3’-end polyuridylation of U6 snRNA plays a role in the 3’-end
maturation (preventing degradation), acts as a binding site for important protein
complexes79, 80, and allows for the U6 snRNA to be degraded after its activity in
pre-mRNA splicing71.
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Figure 5. Non-canonical poly(A) polymerases contain conserved catalytic
domains across species. Poly(A) polymerase Gld2 (H. sapiens) and terminal
uridylyltransferases Cid1 (S. pombe), TUT7, and TUT4 (H. sapiens) all encode
the catalytic nucleotidyltransferase (Ntr) and poly(A) polymerase (PAP) domains,
conserved across all members of the DNA polymerase β-like family. The Ntr
domain is required for nucleotide transfer while the PAP domain is important for
nucleotide specificity. Adapted from Chung, Seidl et al. 20178.

16

1.3.1 Terminal uridylyltransferases TUT4 and TUT7
TUT4 and TUT7, two human homologs, are quite functionally and
structurally redundant. Functional studies have shown that both TUT4 and TUT7
are involved in the uridylation of mRNA and miRNA for degradation, as well as for
miRNA biogenesis. Both TUTases are capable of polyuridylating the 3’-end of
mRNA to signal for degradation41, 65, 70,. Polyuridylation of mRNA has recently
been shown to be crucial in embryonic development by controlling the
degradation of RNA transcripts and therefore controlling the turnover of the
maternal transcriptome24. During group II miRNA biogenesis, both enzymes
monouridylate the pre-miRNA 3’-end allowing for further maturation32, 42, 68.
Alternately, in a Lin28A-dependent pathway, TUT4 and TUT7 recognize Lin28Abound pre-miRNA and polyuridylate the RNA 3’-end, leading to degradation by
the exonuclease Dis3L240, 68, 72. Structurally, TUT4 and TUT7 have a similar
domain layout, sharing 40% amino acid identity. Recently, Faehnle et al. have
crystallized the C-terminus of TUT7 (Figure 6A), which they termed the catalytic
module32. TUT7 catalytic module 2, consisting of amino acid residues 983 to
1365 with a D1060A mutation in the active site and lacking the first CCHC zinc
finger, was crystallized with double stranded RNA (dsRNA) with a 1-nt 3’-end
overhang, mimicking the TUT7 substrate pre-let-7 (Figure 6B)32. This crystal
structure captured TUT7 in its monouridylation activity state, important in miRNA
biogenesis. To observe TUT7 as it would be during poly(U) addition, TUT7
catalytic module 1, which includes the first CCHC zinc finger, was co-crystallized
with non-hydrolyzable UTP (UMPNPP) and an RNA substrate containing a 2-nt
poly(U) 3’-overhang (Figure 6C)32.
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From the crystal structures, Faehnle et al. observed that the C-terminal
catalytic region, containing the Ntr and PAP domains, formed two lobes, an Nlobe and C-lobe32. When in an unbound state, the N-lobe is in an open
conformation, but when a mono(U) or poly(U) RNA substrate is bound, the N-lobe
slightly shifts into a closed conformation, and due to high similarity and
redundancy, Faehnle et al. conclude that TUT4 undergoes the same
conformational changes32.
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Figure 6. Structure of TUT7 as determined by Faehnle et al., 201732. A)
Structure of TUT7 catalytic module, amino acids 963 to 1365. Active site
aspartate residues shown in red. PDB 5W0B. B) TUT7 catalytic module 2 (amino
acids 983 to 1365) with D1060A mutation co-crystallized with dsRNA (purple) to
depict structure during monouridylation activity. The active site aspartate residues
are shown in red, with UTP position in yellow. PDB 5W0O. C) TUT7 catalytic
module with D1060A mutation co-crystallized with poly(U) RNA mimic (purple)
and non-hydrolyzable UMPNPP (yellow). Active site residues (red) D1058 and
A1060 are shown coordinating a single magnesium ion (blue). PDB 5W0N.
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1.4 Terminal uridylyltransferase 4
TUT4, also known as zinc finger CCHC-type containing 11 (Zcchc11), was
first described as a TUTase in 200967, and is the largest human TUTase
containing several important domains (Figure 7). In the C-terminus, three CCHC
zinc fingers (ZnF) are thought to promote RNA binding and flank the active site73,
81

. The active site is composed of two conserved domains, the Ntr domain, which

houses the catalytic aspartate triad, and PAP domain, which plays a role in
nucleotide specificity73, 81. Upstream in the N-terminus, a second catalytic region
is encoded but is believed to be inactive as it lacks an identifiable aspartate triad
required for activity. Also in the N-terminus is the C2H2 ZnF, known to interact
with the RNA binding protein Lin28A73, 81. In 2012, Thornton and colleagues
showed that both the deletion of the C2H2 ZnF and a cysteine to alanine
mutation in the C2H2 ZnF led to basal TUT4 activity, with no increase in
uridylation activity in the presence of Lin28A73. Encoded on the outer ends of the
protein are pneumoviridae (PneumoG) and Atrophin-like domains on the N- and
C-terminus, respectively, both with no known function73. Since their discovery, a
number of RNA substrates have been suggested, with miRNA and mRNA being
the most common.
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Figure 7. TUT4 multi-domain organization. TUT4, 1644 amino acids in length,
contains 10 distinct domains. Three CCHC zinc fingers (ZnF) (black) in the Cterminus have been suggested to be involved in RNA binding. A C2H2 ZnF
(green) in the N-terminus is involved in Lin28 binding. In the C-terminus, the
nucleotidyltransferase (Ntr) (blue) and poly(A) polymerase (PAP) (purple)
domains form the catalytic region. In the N-terminus, a second catalytic region
containing the Ntr (blue) and PAP (purple) is encoded but is lacking an
identifiable aspartate triad. On the extreme N- and C-terminus are the PneumoG
(PnG) (yellow) and Atrophin-like (Atrophin) domains (red), both with no known
role.
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1.4.1 Terminal uridylyltransferase 4 is involved in mRNA degradation
Replication-dependent histone mRNA in eukaryotes terminates in a 3’
stem loop, and is the only mRNA in eukaryotes that is known to not have a
poly(A) tail69, 70. Due to the lack of a poly(A) tail on histone mRNAs, the first step
of mRNA degradation, deadenylation, cannot be initiated. Instead, degradation is
initiated by the 3’-end addition of uridine residues to degrade the mRNA in both a
5’-3’ and 3’-5’ direction (Figure 8A)41, 69, 70. Although other TUTases have been
proposed to participate in this process, TUT4 has been shown to be involved in
histone mRNA degradation69. Schmidt et al. have shown in vivo association
between TUT4 and histone H3 mRNA using immunoprecipitation studies and a
reduction in uridylation of histone mRNA when TUT4 is knocked down69.
Polyuridylation, and as a result degradation, of histone mRNA can occur at both
the end of S phase of the cell cycle, first discovered by Mullen and Marzluff, and
as consequence to DNA replication inhibition41, 65.
Uridylation by TUT4 also occurs on mRNAs with a poly(A) tail on the 3’end (Figure 8B). Lim et al. discovered that uridylation occurs more frequently on
poly(A) tail mRNAs shorter than 25 nts in length65. In in vivo siRNA knockdown
experiments of TUT4, polyuridylation was decreased by 3.7-fold, especially on
mRNA with poly(A) tails consisting of 5-25 adenine residues65. Polyuridylation of
short poly(A) tails occurs on mRNA to accelerate the decay process24, 65, 82.
PABP regulates mRNA stability, including degradation, by interacting with eRF3,
a termination factor22. Every translation event of an mRNA results in the
shortening of the 3’-poly(A) tail, leading to degradation22. When the poly(A) tail
becomes too short (less than 25 nts), PABP can no longer stably bind to the
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poly(A) tail24. This leads to the recruitment of TUT4 and polyuridylation of the
mRNA 3’-end24. Following polyuridylation, the Lsm1-7 (like-Sm proteins)
complex, which has an affinity to bind to uridyl residues, will bind to the mRNA 3’end24, 65 (Figure 8B). Binding of this protein complex to the poly(U) tail is the
beginning step in the 5’-3’ decay pathway24, 65. Lsm1-7 binding is followed by
decapping of the 5’-end, allowing Xrn1, a 5’-exonuclease, to digest the mRNA8,
24, 65

(Figure 8B).
Recently, Morgan et al. discovered the importance of mRNA uridylation in

oocyte formation and maturation24. Interestingly, TAIL-seq experiments of
germline vesicle (GV) oocytes and somatic mouse tissues revealed that GV
oocytes have the highest polyuridylation to monouridylation ratio24. Studying the
role of TUT4 (and TUT7) in oocyte maturation, Morgan and colleagues mutated
mouse alleles, creating several different allele combinations, including a TUT4/7
knockout (TUT4/7cKO) allele24. They observed a lack of early embryonic
development in the TUT4/7cKO oocytes24. Investigating into the role of TUT4
further, expression of catalytically inactive TUT4 protein displayed the same
phenotype as the knockout mice24.

24

A)
TUT4

5’

3’

TUT4

UUUU

5’

3’

Histone mRNA

Degraded
Histone mRNA

B)
TUT4

TUT4

5’

AAAA

3’

AAAAUUUU

3’

5’

mRNA (<25A)

mRNA (<25A)

Xrn1

Xrn1
5’

Lsm1-7
1

7
6
5

5’

2
3
4

5

4

3’

2

6
AAAAUUUU
3
5

2

mRNA (<25A)

1

7

1

7

AAAAUUUU
6
3

4

3’

mRNA (<25A)

Degraded
mRNA

Figure 8. TUT4 polyuridylates mRNA to initiate decay pathway. A)
Polyuridylation of histone mRNA initiates a decay pathway. TUT4 uridylates the
3’-end, after the stem loop. Degradation can occur in either the 5’-3’ or 3’-5’
direction. B) Polyuridylation of mRNA with short poly(A) tails leads to
degradation. TUT4 polyuridylates the 3’-end of mRNA, adding to the poly(A) tail.
Lsm1-7 complex preferentially binds to the poly(U) tail, recruiting the exonuclease
Xrn1, initiating the 5’-3’ decay pathway.
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1.4.2 Terminal uridylyltransferase 4 is a regulator of group II miRNA biogenesis
A well-studied function of TUT4 is its involvement in the biogenesis of
group II miRNA (Figure 9). Primary miRNA (pri-miRNA) is processed in the
nucleus into pre-miRNA by RNase III Drosha and co-factor Pasha (DGCR8), a
holoenzyme, resulting in a hairpin double-stranded RNA structure, before being
exported into the cytoplasm by exportin 527, 42, 64, 83, 84, 85. Two different groups of
pre-miRNAs can be exported out of the nucleus. In group I pre-miRNA, the premiRNA exported has a 2-nt 3’-overhang, recognized by Dicer for further
processing86, 87. Dicer binds the 5’- and 3’-ends of pre-miRNAs in the 5’- and 3’pockets of Dicer’s PAZ domain, cleaving 22 nts from the pre-miRNA 5’-end27, 42,
83

. In group II pre-miRNA, the pre-miRNA only has a 1-nt 3’-overhang. For the

maturation pathway of group II pre-miRNA, TUT4 is recruited and monouridylates
the 3’-end of the pre-miRNA to create the required 2-nt 3’-overhang42, 64 (Figure
9). Dicer is able to recognize the pre-miRNA, cleaving it into mature miRNA,
allowing for the incorporation of one of the miRNA strands into an RNA-induced
silencing complex (RISC) by Argonaute proteins83, 88. Incorporation into a RISC
complex leads to the suppression of the target gene expression83.
In an alternate pathway, the RNA binding protein Lin28A binds to the
group II pre-miRNA and recruits TUT4, which will polyuridylate the pre-miRNA89.
Binding between Lin28A and the pre-miRNA terminal loop occurs through a
GGAG motif, conserved in pre-miRNA27, 42. This interaction blocks Dicer from
processing the pre-miRNA into mature miRNA40, 42, 89. Recruitment of TUT4
results in the interaction between the C2H2 ZnF of TUT4 and Lin28A, resulting in
polyuridylation of the pre-miRNA 3’-end90. Polyuridylation of pre-miRNA triggers a
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decay mechanism. The poly(U) tail is recognized by Dis3L2, a 3’-5’ exonuclease,
which will rapidly degrade the pre-miRNA89, 90, 91 (Figure 9). The function of TUT4
in the pre-miRNA biogenesis pathway has been well-studied in reference to the
group II miRNA let-727, 32, 40, 72.
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Figure 9. TUT4 involvement in miRNA maturation and degradation pathway.
Group II pre-miRNA exported out of the nucleus contains a 1-nt 3’-overhang,
requiring further processing. In a monouridylation pathway, TUT4 adds a single
uridine residue to the 3’-end of pre-miRNA, allowing for recognition by Dicer and
further processing by Argonaute (AGO) proteins and incorporation into RNAinduced silencing complex (RISC). In an alternate, Lin28A-dependent pathway,
Lin28A RNA binding protein binds to the pre-miRNA, recruiting TUT4 to
polyuridylate the 3’-end of the pre-miRNA. The poly(U) tail is recognized by
Dis3L2, a 3’-5’ exonuclease, and degraded.
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1.5 TUT4 is a possible therapeutic target in cancer
MiRNA uridylation, especially polyuridylation, must be tightly regulated to
prevent oncogenesis. The uridylation pathway of the group II miRNA let-7 has
been well studied due to its function as an important tumour suppressor in
several oncogenic pathways including HMG2A, MYC, and RAS92, 93. Lin28A, an
important RNA binding protein in the miRNA degradation pathway, is a known
suppressor of let-7 miRNA maturation92, 94. Reduced let-7 levels, caused by an
overexpression of Lin28, have previously shown to be related to several different
types of cancer92, 94, 95, 96. Interestingly, pri-miRNA let-7 has been shown to still
be produced, while it is only the mature miRNA levels that are affected94. When
this pathway is regulated, Lin28-dependent let-7 degradation is required for
normal development92. In cancers where Lin28A is overexpressed, Lin28A
outcompetes Dicer for pre-let-7 binding, recruiting TUT4 into the let-7 degradation
pathway which results in metastatic tumour formation97. Piskounova and
colleagues have previously shown that TUT4 is a potential therapeutic target in
cancer cells where Lin28A is expressed92. When TUT4 is depleted, the
invasiveness of T47D breast cancer cells with overexpressed Lin28A was
reduced, due to an increase in mature let-7 miRNA levels92. Thus, TUT4 is a
potential target for small molecule inhibitors as future chemotherapeutics.
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1.6 TUT4 N-terminal domain activity plays a role in the cell cycle

Most studies on TUT4 indicate that the catalytic function of TUT4 is
dependent on its C-terminal catalytic region (Ntr and PAP domains), and that the
N-terminal Ntr and PAP domains are catalytically inactive. In 2011, Blahna et al.
discovered a biological function of the N-terminal region of TUT4. Previously,
Blahna et al. showed that TUT4 uridylated miRNA-26a (miR-26a), an miRNA
which has cell cycle protein targets67. This polyuridylation activity leads to the
degradation of miR-26a, controlling the expression of the cytokine IL-667. This
TUT4 activity intrigued Blahna et al., leading to an investigation of the potential
role of TUT4 in cell proliferation. In vivo experiments, studying the role of TUT4 in
H1299 lung epithelial cells, confirmed the importance of TUT4 in cell
proliferation74. A knockdown of TUT4 expression using siRNA showed a
significant decrease in cell proliferation74. Flow cytometry experiments, analyzing
the stages of the cell cycle, showed an increase of the TUT4 knockdown cells
accumulating in the G1 phase74. Overexpression of TUT4 had an opposite effect
on H1299 cells in vivo, with an increase of progression into the S phase of the
cell cycle74. Immunoblots indicated TUT4 expression has a direct effect on cyclin
A, a protein involved in cell cycle progression74. Surprisingly, a catalytically dead
mutant of TUT4 did not affect the cell cycle progression of H1299 cells, as well as
no difference in cyclin A expression74. H1299 cells transfected with truncations of
TUT4 either missing the N- or C-terminal regions, termed Zcchc11-DN and
Zcchc11-DC respectively, showed that overexpression of the TUT4 N-terminal
domains had an effect on the cell cycle, similar to that of the full-length protein74.
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Interestingly, their research led to the discovery of N-terminal region activity and
its effect on the cell cycle74. Blahna and colleagues concluded that the N-terminal
domains of TUT4 had a biological activity in the regulation of cell cycle
development that was independent of TUT4’s uridylation activity74.
1.7 Rationale
The reason behind the existence of two encoded Ntr-PAP catalytic regions
in both the N- and C-termini of TUT4 is unknown yet intriguing. In 2004,
complementary DNA (cDNA) experiments performed by Toshio Ota and
colleagues revealed the existence of a TUT4 isoform, termed TUT4-isoform 298.
The discovery of TUT4-isoform 2 was part of a large-scale study, the “full-length
long Japan” (FLJ), which created a collection of characterized cDNA from
approximately 21,000 clones98. This isoform, which is 719 amino acids in length,
is identical to the full-length TUT4, or TUT4-isoform 1, in the first 684 amino
acids. TUT4-isoform 2 differs, however, in the last 35 amino acids, from amino
acid 685 to 719. In 2009, follow-up experiments, focused on the alternative
splicing of cDNA, mapped out the isoform to two separate locus99. The first 684
amino acids were located on the minus strand of chromosome 1, while the last 35
amino acids were located on the plus strand of chromosome 1699. While
intriguing, it is unclear whether this isoform exists in vivo.
While TUT4-isoform 2 may or may not be a naturally existing isoform,
many splicing variants do occur, some only containing the N-terminal domains of
TUT4. Experimental data from the NCBI Aceview database has shown the
existence of 24 spliced, differentially spliced, or partial mRNA variants of TUT4,
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with 14 of them resulting in the ability to encode proteins at a high level100 (Figure
10). These 14 mRNA variants produce 15 different isoforms, some of them only
containing the N-terminal domains100. This raises questions as to what the
function of the N-terminal catalytic region is since it is lacking an identifiable
aspartate triad.
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Figure 10. The existence of 24 different TUT4 splicing variants. NCBI
Aceview database of naturally occurring TUT4 isoforms. Gene expression of
isoforms is from 15 different primate species and 16 different tissues. TUT4
exists as 25 different isoforms, including 18 alternatively spliced and 7 unspliced
variants100.
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1.8 Hypothesis and Aims
The importance of the activity of the N-terminal region in cell proliferation74
and the existence of splicing variants encoding only the N-terminal domains
raises the question of the function of the TUT4 N-terminal catalytic region. The Nterminal Ntr domain lacks an identifiable aspartate triad, and its catalytic function
remains to be studied. I hypothesize that the N-terminal region is catalytically
active and capable of uridylation activity. I will test my hypothesis with the
following three aims:
Aim 1: Characterization of TUT4 N-terminal domain activity- I will clone and
purify a truncated TUT4 variant encoding only the N-terminal domains. Following
TUT4 N-terminal protein purification, I will use an activity assay utilizing
radioactive [a-32P]-UTP and various RNA substrates to elucidate whether the Nterminal catalytic region has the capability to uridylate RNA.
Aim 2: Mutational analysis and kinetic characterization- Once the activity of
the N-terminal region is determined, I will mutate the proposed N-terminal active
site residues accordingly to either diminish or introduce uridylation activity. If the
TUT4 N-terminal wild-type (WT) protein or mutants display uridylation activity, a
radioactive time course assay will be performed to determine the initial velocity of
the active protein.
Aim 3: Characterization and kinetic analysis of TUT7 N- and C-terminal
domains- Following TUT4 characterization, I will investigate the activity of the
TUT7 N- and C-terminal catalytic domains, which are believed to be redundant to
TUT4.
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Chapter 2: Methods
2.1 Cloning
To express the N-terminal domains of TUT4 (TUT4-N), the segment
encoding amino acids 1 to 678 of TUT4 was cloned into an expression vector for
protein production in Escherichia coli (E. coli). The TUT4-N construct was cloned
using the plasmid HsCD00347737 from the Harvard PlasmID Database as a
template for gene amplification. Primers (TUT4-N FWD: 5’ATTAGGATCCATGGAAGAGTCTAAAACC-3’; TUT4-N REV: 5’TTTAGCGGCCGCCTATGAAAATGGATCTTCAATGG-3’) were designed to
amplify the gene segment consisting of nucleotides 1 to 2034 (amino acids 1 to
678) and add BamHI and NotI restriction sites to the 5’- and 3’-ends of the PCR
product, respectively. The gene segment was created using Polymerase Chain
Reaction (PCR) with Phusion polymerase (New England Biolabs #M0530L)
according to manufacturer’s directions. The thermocycler protocol began by
initially denaturing the DNA at 98°C for 30 seconds (sec.), followed by 30 cycles
of [98°C for 10 sec., 55°C for 30 sec., and 72°C for 30 sec/kb] to denature,
anneal and extend the DNA segment. A final extension at 72°C for 10 minutes
(min.) ensures full-length amplification of the gene segment. Successful
amplification was verified by gel electrophoresis on a 1% agarose gel with
ethidium bromide at 140W in 1x TAE buffer (10x (pH 8.0): 40 mM Tris-acetate, 1
mM ethylenediaminetetraacetic acid (EDTA)). The PCR products were purified
using the GeneJET PCR Purification Kit (Thermo Scientific K0702). For protein
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expression, the PCR product was cloned into the expression vector pGEX-6p2.
The pGEX-6p2 vector encodes an N-terminal Glutathione S-transferase (GST)
tag. The TUT4-N PCR product and pGEX-6p2 vector were digested with
restriction enzymes BamHI (New England Biolabs #R3136S) on the 5’-end and
NotI (New England Biolabs #R3189L) on the 3’-end in Cutsmart buffer (New
England Biolabs # B7204S). Following digestion, the DNA was diluted with 6xDNA loading dye and analyzed by 1% agarose gel electrophoresis. The correct
DNA band was cut out of the gel and gel extracted using the GeneJET Gel
Extraction Kit (Thermo Scientific K0692). The DNA concentration for both the
PCR segment and the pGEX-6p2 vector were determined using the Nanodrop
2000c Spectrophotometer (Thermo Scientific). TUT4-N and pGEX-6p2 vector
were ligated in a 3:1 ratio using T4 DNA ligase (New England Biolabs #M0202L)
at 37°C for 1 hour, followed by heat-shock transformation into TOP10 competent
cells. The cells were spread on Luria-Bertani (LB) agar plates containing 100
µg/mL ampicillin (AMP) and incubated overnight at 37°C. After transformation, up
to 15 colonies are picked and resuspended in 50 mL of double distilled water
(ddH2O). PCR of each colony was performed using Taq DNA polymerase
(GeneDireX MB101A-0500) according to manufacturer’s directions and the 5’pGex and 3’-pGex sequencing primers (5’-pGEX primer: 5’GGGCTGGCAAGCCACGTTTGGTG-3’; 3’-pGEX primer: 5’CCGGGAGCTGCATGTGTCAGAGG-3’). PCR products were analyzed by 1%
agarose gel electrophoresis for confirmation of successful ligation. If ligation of
the gene segment into the pGEX-6p2 vector was successful, a band at the
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correct DNA size will be visualized on the agarose gel. Empty pGEX-6p2 vector
DNA is run with the colony PCR DNA as a negative control. Colonies containing
the PCR product were grown overnight in 5 mL of LB with 100 µg/mL AMP and
isolated by miniprep using the GeneJET Plasmid Miniprep Kit (Thermo scientific
K0503) before prepared DNA samples were sent to Genewiz for sequencing.
2.2 Escherichia coli competent cells and transformation
2.2.1 Chemically competent cells
TOP10 and BL21 codon plus (C+) E. coli cells were made competent by
the RbCl2 method. E. coli cells were grown aerobically in 250 mL of sterilized LB
medium. BL21 C+ E. coli cells were grown with chloramphenicol (CM). When the
culture reached an optical density at 600nm (OD600) of 0.6, cells were harvested
by centrifugation at 6,000 x g for 10 min. at 4°C. The cell sediment was
resuspended in 100 mL of TFB1 pH 5.8 (30 mM Potassium acetate, 10 mM
CaCl2, 50 mM MnCl2, 100 mM RbCl2, 15% glycerol) and incubated on ice for 5
min. Following incubation, the cells were centrifuged at 3,000 x g for 5 min. at
4°C, and the cell sediment was resuspended in 2 volumes of TFB2 pH 6.5 (10
mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% glycerol) and incubated on ice for
30 min. The cell suspension was divided into 40 μL aliquots in pre-chilled 1.5 mL
Eppendorf tubes. The cell aliquots were stored at -80°C.

2.2.2 Heat-shock transformation
1 μL of DNA was incubated with 40 μL of chemically-competent E. coli
cells and incubated on ice for 20 min. Following incubation on ice, the cells were
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subjected to heat-shock at 42°C for 45 sec. and placed back on ice for 2 min. 1
mL of LB was added to the cells and incubated at 37°C for 1 hour at 300 rpm
(Thermomix compact machine). After incubation, 100 μL of cells were spread
onto an LB agar plate with the required antibiotics. The remaining suspended
cells were centrifuged at 16,000 x g for 2 min. The supernatant was removed,
and the cell sediment was resuspended in 100 μL of fresh LB and spread onto an
LB agar plate with the required antibiotics. The plates were incubated overnight
at 37°C.
2.3 Site-directed mutagenesis
Mutagenesis of D412A, N414A, D416A, and R468A, and a C-terminal 6histidine (His6) tag insertion were performed using site-directed mutagenesis
PCR following the method outlined by Edelheit et al. 2009101. Forward and
reverse primers were designed with complementary regions 15-20 nts upstream
and downstream of the mutation site. The mutation is introduced into the
sequence by PCR using primers with a mismatched codon sequence at the site
of interest. This mismatch will change the coding sequence to a new amino acid
after translation. For the His6 insertion, instead of a sequence mutation, a 6histidine sequence was inserted into the plasmid sequence at the site of interest.
The primer sequences are listed in Table 2, as well as the codon change. PCR
was performed with two separate single-primer reactions for the forward and
reverse primers using Phusion polymerase as follows: 94°C for 2 min., [94°C for
40 sec., 55°C for 40 sec., 72°C for 30 sec./kb of plasmid] x30 cycles, and 37°C
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infinite. Single-primer reactions prevent the unintended annealing of the primers
and formation of “primer dimers”. Forward and reverse primer reactions were
combined and incubated at the following temperatures: 95°C for 5 min., 90°C for
1 min., 80°C for 1 min., 70°C for 30 sec., 60°C for 30 sec., 50°C for 30 sec., 40°C
for 30 sec., 37°C for infinity. This allows for annealing of the parental DNA
strands and the newly synthesized DNA strands. Final products were DpnI (New
England Biolabs #MR0176S) digested for 2 hours at 37°C. DpnI digests
methylated parent DNA, ensuring only the newly synthesized PCR products
remain. This was followed by transformation using the heat-shock method in
TOP10 competent cells. Transformed cells were spread on LB plates with 100
µg/mL AMP and incubated overnight at 37°C. 5-10 colonies were picked and
grown in 5 mL LB overnight cultures with 100 µg/mL AMP and purified by plasmid
miniprep using the GeneJET Plasmid Miniprep Kit (Thermo Scientific, K0503)
according to manufacturer’s instructions and sent for sequencing (Genewiz).
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Table 2. Primer sequences for site-directed mutagenesis
Mutant

Primer

D412A

Forward

5’-GCTCTGAAAAGTAGTGCAGTTAATATAGATATA-3’

Reverse

5’-TATATCTATATTAACTGCACTACTTTTCAGAGC-3’

Forward

5’-CTGAAAAGTAGTGATGTTGCAATAGATATAAAA
TTTCC-3’

Reverse

5’-GGAAATTTTATATCTATTGCAACATCACTACT
TTTCAG-3’

Forward

5’-GCTCTGAAAAGTAGTGATGTTAATATAGCAATA
AAATTTCCTCCCAAGATGAATCATCC-3’

Reverse

5’-GGATGATTCATCTTGGGAGGAAATTTTATTGCT
ATATTAACATCACTACTTTTCAGAGC-3’

Forward

5’-GTTGTGGTGTGCAGAGATCGAAAAAGTGGTTT
ACTTTGTGCAGTGAGTGCAGGAAACGATATGGCATGT
CTCACTACTGATTTACTTACTGCCC-3’
5’-GGGCAGTAAGTAAATCAGTAGTGAGACATGCC
ATATCGTTTCCTGCACTCACTGCACAAAGTAAACCACT
TTTTCGATCTCT GCACACCACAAC-3’
5’-GAAGATCCATTTTCACATCATCACCATCACC
ACTAGGCGG CCGCATCGTG-3’

N414A

D416A

R468A

Reverse
His6

Forward
Reverse

Sequence

Codon
Change
GAT to GCA

AAT to GCA

GAT to GCA

AGA to GCA

His6 addition

5’-CACGATGCGGCCGCCTAGGGTGATGGTGAT
GATGTGAAAATGGATCTTC-3’

2.4 Purification of TUT4 proteins
To purify the N-terminal domains of TUT4, TUT4-N in pGEX-6p2-His was
transformed into BL21 C+ competent E. coli cells via heat-shock and grown on
LB plates containing 100 µg/mL AMP and 34 µg/mL CM. A colony was selected
and grown in 50 mL LB culture containing 100 µg/mL AMP and 34 µg/mL CM
overnight. 10 mL of the overnight culture was transferred to a 1 L flask containing
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LB supplemented with 100 µg/mL AMP and 34 µg/mL CM. Five 1 L cultures were
grown, using 10 mL of cells/L from the 50 mL pre-culture, to an OD600 of 0.6,
and protein expression was induced with 250 µM of isopropyl-b-D-1thiogalactopyranoside (IPTG). The cells were collected by centrifugation in 1-L
bottles at 9,000 x g for 10 minutes. The cell sediment was transferred to 50 mL
falcon tubes and centrifuged at 3,000 x g for 15 minutes. The cells were stored at
-80°C.
The cells were resuspended in 10 mL of lysis buffer (50 mM Tris-HCl pH
8.0, 300 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 0.1% Triton X-100,
5 mM MgCl2, 10% glycerol) per litre of cells and lysed via a French Pressure Cell.
For French Press cell lysis, resuspended cells are applied to the French pressure
cell and placed under constant pressure of 1000 psi, forcing cell suspension
through a small flow outlet. Soluble protein was separated from cell debris using
ultracentrifugation (Beckman Coulter Ultracentrifuge) at 150,000 x g for 1 hour
and the supernatant containing the protein was collected. Proteins were first
purified on the AKTA FPLC (GE) using a pre-packed GSTrap FF 5 mL
glutathione column (GE 17-5131). Non-specific proteins were washed off the
column with Buffer A (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 0.1 mM EDTA, 1
mM DTT, 0.1% Triton X-100, 5 mM MgCl2, 10% glycerol), and TUT4-N protein
was eluted in a gradient elution from 0-100% Buffer B (50 mM Tris-HCl pH 8.0,
300 mM NaCl, 5 mM MgCl2, 10% glycerol, 10 mM glutathione) over 45 mL.
Elutions were collected in 2 mL fractions. Fractions were analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for the presence
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of TUT4.
Elution fractions containing the TUT4-N proteins were further purified
using the C-terminal His6 tag on a nickel-nitrilotriacetic acid (Ni-NTA) affinity
column. The protein was loaded onto HisPurä Ni-NTA resin (Thermo Scientific
88222) and washed with Buffer C (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM
MgCl2, 50 mM imidazole, 10% glycerol). Protein was eluted in 1 mL fractions with
Buffer D (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5 mM MgCl2, 500 mM
imidazole, 10% glycerol). Fractions were analyzed by SDS-PAGE for the
presence of TUT4.
Elution fractions were concentrated using a Vivaspin 6 ultrafiltration
concentrator with a 10,000 MWCO (Sartorius VS0601) at 4,000 x g and dialyzed
using Biotech RC Tubing dialysis membrane (Spectra/Por® Biotech Dialysis
Membrane 133342) overnight into Buffer E (50 mM Tris-HCl pH 8.0, 300 mM
NaCl, 5 mM MgCl2, 10% glycerol). The protein was further concentrated using
the AmiconÒ Ultra-0.5mL Centrifugal Filters UltracelÒ 3K concentrator (Millipore
Sigma UFC500324). All TUT4-N mutants were purified following the same
procedure. Samples from each step of the purification of the TUT4-N proteins
were analyzed by SDS-PAGE as described below.
2.5 SDS polyacrylamide gel electrophoresis
Protein samples were diluted in 3x sodium dodecyl sulfate (SDS) loading
dye and boiled for 5 min. at 95°C. Samples were loaded on an 8% separating
SDS-PAGE gel with a 5% stacking gel and run at 100V in SDS running buffer
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until the loading dye front runs off the gel. The gel was stained in Coomassie
Blue for an hour, followed by an incubation in destain for an hour. The SDSPAGE gel was imaged on the Chemidoc MP imaging system (Bio-Rad).
2.6 Bradford assay
BSA protein standard (0 mg, 2.5 mg, 5 mg, 10 mg) was diluted in ddH2O
to a final volume of 100 μL. 5 μL of purified protein was diluted to a final volume
of 100 μL. 5x Bradford reagent (Bio-Rad, #5000006) was diluted to 1x and 1 mL
of reagent was added to each Eppendorf tube and mixed well. The Eppendorf
tubes were incubated for 15 min. at room temperature. Absorbance at 595 nm
was measured for each standard and the purified protein. The absorbance of the
standards was plotted against protein concentration to determine the standard
curve. Using the linear equation of the standard curve, the concentration of the
purified protein was calculated.
2.7 Western blot
Purified proteins (TUT4-N, D412A, N414A, and D416A) were run on an
8% SDS-PAGE gel, as described above. After SDS-PAGE, the gel and Whatman
paper was pre-incubated in transfer buffer for 15 min. PVDF membrane
(ImmobilonÒ -FL Transfer Membrane IPFL00010) was activated by incubation in
100% methanol for 10 min. before subsequent incubation in transfer buffer. This
pre-incubation was followed by transferring of the proteins to the PVDF
membrane using the Trans-BlotÒ Turboä transfer system (Bio-Rad). The gel was
placed on top of the PVDF membrane between three pieces of Whatman paper
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on each side. The layered membrane and gel are placed in the cassette of the
Trans-BlotÒ Turboä transfer system and the protein was transferred at 1.3A and
25V for 15 min. The membrane was subsequently incubated in blocking solution
(5% skim milk in 1x PBS-tween (10% 10x-PBS [1.37 M NaCl, 27 mM KCl, 100
mM Na2HPO4, 20 mM KH2PO4], 0.1% Tween20, ddH2O) for 1 hour to prevent
non-specific binding, followed by incubation with the primary anti-TUT4 antibody
(Proteintech 18980-1-AP) (1:200 in blocking solution) overnight at 4°C with
agitation at 40 rpm on a Standard Analog Shaker (VWR). The membrane was
washed 3 times in wash solution (1% skim milk in 1x PBS-tween) for 5 min. This
was followed by incubation with the secondary antibody anti-rabbit IgG HRPlinked F(ab’)2 fragment (GE life sciences NA9340V) (1:500 in wash solution) for 2
hours at room temperature with agitation. The blot was washed with 1x PBStween 3 times for 5 min. before imaging. Antibody binding was visualized, taking
advantage of the reaction catalyzed by horseradish peroxidase (HRP), which is
linked to the secondary antibody. In this reaction, HRP catalyzes the oxidation of
luminol in the presence of hydrogen peroxide, an oxidizing agent, which in turn
emits light102, 103. This light emission can be imaged and is correlated to the
location of the protein immobilized on the membrane. The blots were imaged
using Clarity Maxä ECL substrate (Bio-Rad 1705062S) on the Chemidoc MP
imaging system.
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2.8 TUT4 enzyme activity assay

2.8.1 End-point activity assay
To test the enzymatic activity of TUT4 protein variants, a radioactive
activity assay was performed, monitoring the addition of a radiolabelled
nucleotide to a substrate RNA. The purified proteins (TUT4-N, D412A, N414A,
D416A, and R468A) were individually incubated with 3.2 mM MgCl2, 1 mM DTT,
1 µM RNA, and 0.5 µL of 3.3 µM [a-32P]-UTP (Perkin Elmer EasyTides® Uridine
5’-triphosphate [a-32P] BLU507H25OUC) at 37°C for 30 min. RNAs miR-122
(Sigma), 15A RNA (Sigma), let-7a (Sigma), and pre-let-7a (purified in lab) were
used. The reactions were stopped using 2x RNA loading dye (95% v/v
formamide, 0.1% w/v xylene xyanol, 0.1% w/w bromophenol blue, 10 mM EDTA).
Uridylated RNA products were separated on a 12% polyacrylamide gel at 30W
for 2 hours and exposed overnight on a phosphor-imaging screen. Radioactivity
was imaged using the Storm 820 imager (Molecular Dynamics). For nucleotide
size reference, radiolabelled RNA ladder was used (Invitrogen Decade™ Markers
System 7778a).

2.8.2 TUT4 inhibitors
Known TUT4 inhibitors were used in the radioactive activity assay
reactions to determine the effect on TUT4-N. These inhibitors were validated
through experimentation by Lin and Gregory (2015)104. The two most successful
selective TUT4 inhibitors are aurothioglucose (auro) and IPA-3. In the end-point
activity assay, auro (Sigma A0606-5MG) and IPA-3 (Sigma I2285-5MG) were
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added to a final concentration of 0.1 μM.

2.8.3 PUP time course activity assay
Commercial PUP (New England Biolabs #M0337S) was incubated with 3.2
mM MgCl2, 1 mM DTT, 1 µM 15A RNA, 0.5 µL of 1.65 µM [a-32P]-UTP, and 0.95
µM cold UTP. The reaction was stopped using 2x RNA loading dye at 1, 2, 5, 10,
and 20-min. time points. The reaction products were separated on a 12%
polyacrylamide RNA gel and exposed overnight at -80°C on a phosphor-imaging
screen. Standards of defined amounts of radiolabelled nucleotide (3.3, 33, 330,
3300 & 33000 pM) were spotted on Whatman paper and exposed with the gel.
The radioactivity was imaged using the Storm scanner and the product
concentration of radiolabelled RNA was quantified and plotted on a scatter plot. A
dilution factor of 24 was taken into consideration for quantification purposes.

2.8.4 TUT4-N time course activity assay
12 μg (0.6 mg/mL) of TUT4-N and mutant protein was incubated in a 20
µL reaction with 3.2 mM MgCl2, 1 mM DTT, 1 µM 15A RNA, and 1 μL [a-32P]UTP. The reaction was incubated for 30 sec. at 37°C before addition of TUT4
enzyme. The reaction was stopped with 2x RNA loading dye at 2, 5, 10, 20, 30,
and 60-min. time points. The reaction products were separated on a 12%
polyacrylamide gel at 30W, followed by exposure on a phosphor-imaging screen
overnight at -80°C. Standards of defined amounts of radiolabelled nucleotide
(3.3, 33, 330, 3300 & 33000 pM) were spotted on Whatman paper and exposed
with the gel. The radioactivity was imaged using the Storm scanner and the
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product concentration of uridylated RNA was quantified using the standards and
plotted on a scatter plot. Using the slope from the graph, the initial velocities and
specific activities of the TUT4-N and mutants were calculated.
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Chapter 3: Results
3.1 TUT4-N was cloned into an E. coli expression vector
To study the N-terminal region of TUT4, a TUT4 construct containing only
the N-terminal domains was cloned using the plasmid HsCD00347737 as
described in Chapter 2 (Figure 11). The construct, which will be referred to as
TUT4-N, encodes amino acids 1 to 678 (Figure 11A) and was cloned into a
pGEX-6p2 vector with an N-terminal GST tag. For more efficient purification, a Cterminal His6 tag was incorporated using site-directed mutagenesis, as described
in Chapter 2. The TUT4-N plasmid was transformed into BL21 C+ E. coli cells for
expression.

3.1.1 The N-terminal domain lacks an identifiable catalytic aspartate triad
An amino acid sequence alignment of the N- and C-terminal domains of
TUT4 was performed to determine which amino acids in the N-terminal Ntr
domain correspond to the catalytic aspartate triad in the C-terminal Ntr domain.
The catalytic triad, common to all nucleotidyltransferases and described in detail
in Faehnle et al. 201732, of the C-terminal Ntr domain consist of aspartates
D1009, D1011, and D1070. The alignment of other terminal uridylyltransferases
with the N- and C-terminals of TUT4 show that this catalytic triad is conserved
across species (Figure 11B). Our sequence alignment further shows that the
corresponding amino acids in the N-terminal Ntr domain are D412, N414, and
R468 (Figure 11B). Two of the three aspartates that are part of the catalytic triad
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in the C-terminal Ntr domain are not encoded in the corresponding positions in
the N-terminal Ntr domain.
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A)
PnG

C2H2
ZNF

Ntr

PAP

CCHC
ZNF

Ntr

PAP

CCHC CCHC
ZNF ZNF Atrophin

Full Length
TUT4

TUT4-N

B)

Cid1
Gld2
TUT4 C-terminal Ntr
TUT7 C-terminal Ntr
TUT4 N-terminal Ntr
TUT7 N-terminal Ntr

Cid1
Gld2
TUT4 C-terminal Ntr
TUT7 C-terminal Ntr
TUT4 N-terminal Ntr
TUT7 N-terminal Ntr

Figure 11. TUT4 N-terminal domain layout and sequence alignment. A) Fulllength TUT4 encodes several zinc fingers (ZnF), and two copies of the catalytic
Ntr and PAP domains. The expression construct for the N-terminal region (TUT4N) encodes the TUT4 N-terminal catalytic region with the Ntr domain (blue) and
the PAP domain (purple). The N-terminal C2H2 ZnF (green) was shown to
interact with Lin28. The PneumoG (PnG) domain (yellow) has no known activity.
B) Sequence alignment of conserved aspartate residues in TUTases. The
catalytic triad is conserved in TUTases across species (Cid1 in yeast, Gld2 PAP
in humans). The TUT4 (and TUT7) N-terminal Ntr domain lacks two of the
aspartate residues, with an asparagine (Asn(N)) and arginine (Arg(R)) (or lysine
(Lys(K)) for TUT7) in their place.
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3.2 Purification of TUT4-N

3.2.1 TUT4-N was partially purified
TUT4-N was purified using both glutathione affinity and Ni-NTA affinity
chromatography, as described in Chapter 2, taking advantage of both the Nterminal GST tag and C-terminal His6 tag of the recombinant fusion protein. This
two-step process was performed to remove as many contaminants as possible.
BL21 C+ E. coli cells expressing the TUT4-N protein were lysed with a French
Pressure Cell and proteins were separated from cell debris by ultracentrifugation.
The TUT4-N protein was initially purified by glutathione affinity purification using a
pre-packed GST column (GSTrap FF 5 mL) on the AKTA FPLC purification
system. The protein was eluted with glutathione, and fractions containing protein
of the expected relative molecular mass were identified by SDS gel
electrophoresis and Western blotting with a TUT4-specific antibody. The fractions
containing eluted TUT4-N protein were then further purified by Ni-NTA affinity
chromatography, again followed by SDS gel electrophoresis to identify elution
fractions containing recombinant TUT4-N. After Ni-NTA purification, the fractions
containing TUT4-N protein were dialyzed overnight to be used for downstream
applications. Samples from different steps of the purification process were run on
an SDS-PAGE gel to demonstrate the elimination of non-specific, contaminating
proteins (Figure 12). Ni-NTA elution fractions containing the TUT4-N protein were
concentrated (Figure 13A) and a Bradford assay was performed to determine
TUT4-N protein concentration. The protein yield was generally between 0.1 and
0.2 mg/ L E. coli culture. The protein was concentrated to 0.95 mg/mL.
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Figure 12. Two-step purification process of TUT4-N. Image of an SDS gel of
the TUT4-N purification process. After an initial GST purification, the protein was
further purified by His-tag affinity purification. The relative molecular mass of
TUT4-N is calculated as 105 kDa, and a band is visible at that mass, indicated by
an arrow.
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3.2.2 Expression of TUT4-N was confirmed by Western blot and mass
spectrometry
To verify the identity of purified proteins, a Western blot with an antibody
specific to TUT4 was performed. The TUT4-specific antibody was used as the
primary antibody. The TUT4 antibody is specific for a peptide located in the Nterminal region of TUT4, specifically amino acids 265 to 282. A band was
detected at approximately 105 kDa, which corresponds to the expected relative
molecular mass of GST and His-tagged TUT4-N, confirming the successful
purification of TUT4-N (Figure 13B). The 105 kDa protein was excised from the
gel and analyzed by mass spectrometry (London Regional Proteomics Centre)
(Figure 13C). Mass spectrometry and Western blot confirmed that TUT4-N
protein was in fact purified and was present at 105 kDa. A second, prominent
band at a relative molecular mass of 80 kDa, seen on the SDS-PAGE and
Western blot, could be a result of protein degradation.
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Figure 13. Verification of purified TUT4-N. A) SDS-PAGE and B) Western blot
of concentrated TUT4-N protein. Western blot was performed using a TUT4specific primary antibody. Distinct bands can be seen at 105 kDa and 80 kDa. C)
Mass spectrometry of TUT4-N purification. The 105 kDa protein from the TUT4-N
purification was analyzed by mass spectrometry. The peptides identified by mass
spectrometry are highlighted in red.
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3.2.3 Mock purification
Our two-step purification (GST and His6 tag) did not yield entirely pure
protein, and further purification steps like gel filtration or anion exchange
chromatography led to significant degradation of TUT4-N (data not shown). Since
TUT4-N expresses at very low levels (0.1-0.2 mg/L E. coli culture), and extended
purification protocols lead to degradation of the protein, further purification of
TUT4-N was not successful. To confirm that enzymatic activity is in fact due to
the recombinantly purified protein and not residual contaminants with E. coli
proteins, a mock protein purification was performed. The empty vector (pGex6p2-His) was transformed into BL21 C+ E. coli cells and the protein production
and purification was performed under identical conditions as described for the
TUT4-N purification. The cells were lysed, and the protein was purified using the
same two-step process as the TUT4-N protein (Figure 14). This mock purification
was used as a negative control in the subsequent radioactive activity assay.
From here on, this protein will be referred to as ‘Mock’.
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Figure 14. Mock purification of empty pGEX-6p2-His vector as a negative
control. A) SDS-PAGE of the mock purification process. A band corresponding
to the GST-His protein is visible at the relative molecular mass of 25 kDa, as well
as all bacterial contaminants after both GST and Ni-NTA purification. B) Western
blot of concentrated TUT4-N and Mock protein. TUT4 can be distinctly seen after
Western blot using a TUT4-specific antibody, while no TUT4 protein signal can
be detected in the Mock protein.
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3.3 The TUT4 N-terminal domain is catalytically active

3.3.1 The Cid1 poly(U) polymerase is catalytically active with several RNA
substrates
To establish an activity assay using radioactive nucleotides as substrate,
commercially available poly(U) polymerase (PUP) Cid1 (NEB M0337S) was used
as a positive control. Cid1 is isolated from an E. coli strain carrying the PUP gene
from S. pombe. Cid1 is capable of utilizing UTP for RNA 3’-end labelling as
described previously16, 57. A radioactive activity assay was performed, and Cid1
was incubated with several different RNA substrates and radioactive [a-32P]-UTP
for 30 min. in an end-point reaction. The reaction products were separated by gel
electrophoresis on a 12% polyacrylamide gel, and the radioactive signal of the
uridylated RNA was visualized using phosphor-imaging (Figure 15). ‘No enzyme’
and ‘no RNA’ control reactions were used as negative controls. Polyuridylation
activity can be seen as a distinct ladder of bands for RNA substrates 15A RNA
(15 nts), miR-122 (22 nts), and let-7a (22 nts). Cid1 catalyzed the addition of UTP
to a variety of RNA substrates, including pre-let-7a (70 nts), and total yeast tRNA
(72-95 nts). Very little activity was observed on total RNA extracts from human
cells (HEK293T and MDA-MB-231 breast cancer cells). This demonstrates that
the radioactive activity assay works well in determining enzyme activity, and
therefore will be used to determine TUT4-N activity.
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Figure 15. Cid1 is catalytically active with a variety of substrates. Cid1 is
active with 15A RNA (15 nts), miR-122 (22 nts), let-7a (22 nts), pre-let-7a (70
nts), and total yeast tRNA. No enzyme control contains 1 μM RNA substrate.
Distinct polyuridylation activity can be seen as a ladder of bands for 15A RNA,
miR-122, and let-7a. Radioactive bands seen in all lanes including the negative
controls are common to the assay and stem from the radiolabelled nucleotide.
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3.3.2 TUT4-N is capable of uridylation activity with select substrates
The N-terminal catalytic region of TUT4 is believed to be inactive due to
the lack of an identifiable aspartate triad in the N-terminal Ntr domain. To test the
activity of TUT4-N, I performed a radioactive activity assay, as described in
Chapter 2. Radiolabelled UTP ([a-32P]-UTP) was incubated with TUT4-N and
RNA substrate for 30 min. in an end-point reaction. Reactions without enzyme
(No enzyme) or RNA (No RNA) were performed as negative controls. Four RNA
substrates were used, including the miRNAs let-7a and miR-122, pre-miRNA prelet-7a, and an mRNA poly(A) tail mimic, 15A RNA. Reactions including Lin28A,
an RNA binding protein, or the previously described TUT4 inhibitors
aurothioglucose (auro) or IPA-3104, were performed with miR-122 to determine
their effect on the N-terminal catalytic region of TUT4. TUT4-N displayed
uridylation activity with two of the RNA substrates (Figure 16). Overall, the protein
displayed very little catalytic activity, and high concentrations of proteins were
required (0.6 mg/mL). MiR-122 and 15A RNA were uridylated by TUT4-N, as
visible by the radioactive signal at the correct nucleotide lengths (~23 nts and ~16
nts, respectively). Interestingly, TUT4-N was not active with let-7a and pre-let-7a,
both previously described substrates of the full-length TUT4. Lin28A and
aurothioglucose displayed no effect on the activity of TUT4-N, while the addition
of IPA-3 in the reaction resulted in an increased product formation.

59

nt

No E
nzym
Cell
e
Lysa
te
No R
N
A
mi R
-1
15A 22
R
let-7 NA
p re - a
le
mi R t - 7 a
-1
mi R 2 2 + L i
n
-1
mi R 2 2 + A 2 8
u ro
-1 2 2
+ IP
A-3

TUT4-N

150

pre-let-7a

100
90
80
70
60
50
40
30

miR-122
let-7a

15A RNA

20

10

Figure 16. TUT4-N exhibits uridylation activity. TUT4-N has in vitro uridylation
activity with miR-122 (22 nts) and 15A RNA (15 nts). A single band can be seen
for both reactions at the correct nucleotide length. No activity is seen with let-7a
(22 nts) or pre-let-7a (70 nts). Lin28 has no effect on TUT4-N activity with miR122. No enzyme, no RNA, and cell lysate reactions were used as negative
controls. Radioactive bands seen in all lanes including the negative controls are
common to the assay and stem from the radiolabelled nucleotide.
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3.3.3 DMSO stabilizes TUT4-N and increases product formation
As shown above, the addition of IPA-3 to the enzymatic reaction resulted
in an increase of enzymatic activity. To test whether the increased product
formation observed upon addition of IPA-3 to the reaction was due to IPA-3 or the
solvent DMSO, I carried out a series of activity assays with increasing reactions
of DMSO (5 to 30%). Interestingly, DMSO addition led to an increase in enzyme
activity (Figure 17). As it is unlikely that DMSO participates in the catalytic
reaction, DMSO likely stabilized TUT4-N and allowed for increased turnover
rates.
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Figure 17. DMSO stabilizes TUT4-N and increases its enzymatic activity.
Uridylation activity of TUT4-N with miR-122 (22 nts) increases with increasing
concentrations of DMSO (5 to 30%). The reaction product (uridylated miR-122) is
indicated by an arrow. Radioactive bands seen in all lanes including the negative
controls are common to the assay and stem from the radiolabelled nucleotide.
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3.3.4 Mock protein activity
While TUT4-N was significantly purified in our two-step purification
process, we could not exclude that the observed uridylation activity was due to
potential E. coli protein contaminants. To determine that the activity is in fact from
the TUT4-N protein, reactions were performed using Mock protein, obtained from
a mock protein purification described above. Reactions containing 12 μg (1.2
mg/mL) of Mock protein, double the amount of total protein in the TUT4-N
reactions, and 50 μg (5 mg/mL) of Mock protein, were performed with both miR122 and 15A RNA. ‘No enzyme’ and ‘no RNA’ reactions were used as negative
controls, while TUT4-N with 15A RNA was used as a positive control. As
expected, only the TUT4-N positive control showed uridylation activity, at
approximately 16 nts (Figure 18). This demonstrates that the uridylation activity is
from the presence of TUT4-N and not a contaminating bacterial protein.
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Figure 18. Confirmation of TUT4-N uridylation activity using Mock protein.
No activity is seen with the Mock protein with 15A RNA (15 nts) or miR-122 (22
nts). TUT4-N activity can be seen as a distinct band in a positive control reaction
with 15A RNA. ‘No enzyme’ and ‘no RNA’ reactions were used as negative
controls. Representative image of experiments performed in triplicate.
Radioactive bands seen in all lanes including the negative controls are common
to the assay and stem from the radiolabelled nucleotide.
64

3.4 Mutation of proposed N-terminal active site residues and protein
purification
3.4.1 Mutation of possible catalytically relevant active site residues determined by
sequence alignment
Since an unexpected uridylation activity of the N-terminal domains of
TUT4 was discovered, a sequence alignment was performed to determine which
residues align with the C-terminal catalytic aspartate residues. Within the Nterminal Ntr domain, aspartate 412 (D412), asparagine 414 (N414), and arginine
468 (R468) are proposed to align with the catalytic triad (Figure 19). Interestingly,
just downstream of N414 is an aspartate residue (D416), which we believe could
potentially be involved in the uridylation activity.
To determine if these residues are in fact contributing to TUT4-N
uridylation activity, site-directed mutagenesis was performed, as described in
Chapter 2, to mutate these residues to alanine. In the event that D412, N414,
D416, or R468 are important for activity, alanine mutations should significantly
decrease or eliminate the catalytic activity. These mutants will be referred to as
D412A, N414A, D416A, and R468A from here on.
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D412

N414

D416

TUT4 N-terminus
TUT4 C-terminus

R468

TUT4 N-terminus
TUT4 C-terminus

Figure 19. Sequence alignment of TUT4 N- and C-termini to identify
catalytic residues of the N-terminal Ntr domain. The N-terminal catalytic
region was aligned with the C-terminal catalytic region of TUT4 to determine
which residues are in homologous position to the active site catalytic triad. Nterminal D412, N414, and R468 align with the C-terminal aspartates. N-terminal
D416 is in close proximity to these residues and is of interest.
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3.4.2 Purification of mutants with the similar purity as WT
Once mutation of the N-terminal active site residues to alanine was
confirmed by sequencing, all 4 mutants were transformed into BL21 C+ E. coli
cells. Cells were grown to an OD600 of 0.6, followed by overnight induction with
250 µM IPTG, the same as the TUT4-N protein, as described in Chapter 2. Cells
were lysed using French Press and soluble proteins were isolated and applied to
the GST affinity column. Elutions containing the mutant protein were then applied
to the Ni-NTA affinity column, following the same purification process as the
TUT4-N protein. Purified proteins were concentrated before dialyzing overnight to
remove imidazole. Samples from each step of the purification process were
visualized by SDS-PAGE to ensure purification similar to the TUT4-N protein
(Figure 20A). After dialysis, the mutant proteins were further concentrated, and
the proteins were separated via SDS-PAGE, along with TUT4-N. All proteins
were purified to the same homogeneity (Figure 20B & C) and concentrated. Final
protein concentrations were determined by Bradford assay, with concentrations
of 1.2 mg/mL (D412A), 0.77 mg/mL (N414A), 0.95 mg/mL (D416A), and 0.7
mg/mL (R468A). It is to be noted that while the yields for D412A, N414A, and
D416A were similar to WT (0.2 mg/L E. coli culture), R468A showed a
significantly lower expression rate at 0.03 mg/L E. coli culture. Western blot
analysis of D412A, N414A, and D416A was performed to verify the presence of
TUT4 protein (Figure 21). A TUT4-specific antibody verified the purification of the
TUT4 mutants, as evident by a band at a relative molecular mass of 105 kDa.
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Figure 20. Purification of TUT4-N mutants. A) SDS-PAGE of the purification of
mutant protein D412A. B) SDS-PAGE of concentrated TUT4 mutant proteins
compared to purified concentrated TUT4-N WT protein. TUT4-N WT and mutants
have a relative molecular mass of 105 kDa. C) SDS-PAGE of mutant protein
R468A. R468A had significantly lower expression of 0.03 mg/L compared to WT
TUT4-N.
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Figure 21. Verification of TUT4-N mutants by Western blot. Western blot
analysis using a TUT4-specific antibody to verify the presence of TUT4-N and
mutants. A band at a relative molecular mass of 105 kDa is visible for all proteins
(indicated by upper arrows). A second distinct band is seen at 80 kDa (indicated
by lower arrows).
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3.5 TUT4 mutants are catalytically active
After purification of the TUT4 mutants (D412A, N414A, D416A, and
R468A), radioactive activity assays were performed to determine which residues
were critical for the uridylation activity. Proteins were incubated with [a-32P]-UTP
and different RNA substrates in a 30-min. end-point reaction, as described in
Chapter 2. The reaction products were separated on a 12% polyacrylamide gel
and the radioactive signal was imaged on the Storm scanner. ‘No enzyme’ and
‘no RNA’ reactions were used as negative controls, while reactions with TUT4-N
were used as positive controls.
Surprisingly, all four mutants displayed uridylation activity similar to the
TUT4-N protein. Interestingly, the mutant proteins, as well as the WT protein,
were not active with all RNA substrates but displayed RNA specificity for miR-122
and 15A RNA (Figure 22). Uridylation activity is distinct for D412A and N414A
with 15A RNA and miR-122, but no activity is seen with let-7a or pre-let-7a
(Figure 22A). Since no activity is seen with WT or the D412A and N414A mutants
for let-7a and pre-let-7a, reactions with these RNAs were excluded for D416A
and R468A mutant proteins (Figure 22B & C). Interestingly, it seems that the
D412A and N414A mutants show an increase in miR-122 uridylation of degraded
miR-122 substrate, as seen by a ladder of bands under the nucleotide length of
the full-length miRNA (22 nts).
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Figure 22. TUT4-N mutants display RNA-specific uridylation activity. A)
Uridylation activity of D412A and N414A. Distinct bands of uridylation activity can
be seen with 15A RNA (15 nts) and miR-122 (22 nts). B) Uridylation activity of
D416A with 15A RNA and miR-122. C) Uridylation activity of R468A with 15A
RNA and miR-122. TUT4-N was used as a positive control, while ‘no enzyme’
and ‘no RNA’ were used as negative controls. Radioactive bands seen in all
lanes including the negative controls are common to the assay and stem from the
radiolabelled nucleotide.
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3.6 Mutating N-terminal active site residues has no significant effect on the
activity of TUT4-N
3.6.1 Cid1 adds nucleotides in a time dependent manner
To ensure that the time course activity assay, as described in Chapter 2, is
an accurate means to assess nucleotide addition, Cid1 was used as a positive
control. Since Cid1 is more active than the TUT4-N variants, [a-32P]-UTP was
diluted by a factor of 24 with unlabelled UTP to a final concentration of 1 µM total
UTP. The radioactive assay was performed using 15A RNA, with the reaction
being stopped at time points of 1, 2, 5, 10, and 20 min. The reactions were
separated on a 12% polyacrylamide gel, and the intensities of the radioactive
signals were quantified. Serial dilutions of radiolabelled UTP were spotted on
Whatman paper and exposed with the gel to create a standard curve of the
intensities for quantification of the uridylated RNA product. Once plotted on a
graph (Figure 23), it is evident that Cid1 activity plateaus after 10 minutes at an
average product formation concentration of 52 ± 10 nM. The time course assay
was repeated in triplicate and standard error was calculated. Initial velocity was
calculated to determine the activity of Cid1, with an average of 0.31 ± 0.1 nM/sec.
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Figure 23. Quantification of uridylated product with Cid1. Commercial PUP
Cid1 was used as a positive control for the quantitative radioactive time course
assay. Cid1 is most active within the first 10 min., with its activity plateauing at
approximately 52 ± 10 nM of uridylated product formation. The error represents
one standard error.
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3.6.2 Uridylation activity of TUT4-N and mutants is time dependent and some
mutants display altered activity.
To determine if there is a significant change in the activity of the TUT4-N
mutants compared to WT protein, a radioactive time course assay was performed
with 15A RNA, as described in Chapter 2. This assay measures the product
formation of uridylated RNA at different time points to quantify the activity of the
TUT4-N enzymes. Since the activity of TUT4-N and mutants is much lower than
Cid1, the [a-32P]-UTP was not diluted or supplemented with unlabelled UTP.
Instead, the radioactive end-point activity assay reactions were scaled up 2-fold
to ensure that the reactions could be stopped at several time points for the most
accurate quantification. 12 μg of protein was added to the reaction at a final
concentration of 0.6 mg/mL for TUT4-N and mutants. The reactions were stopped
at time points of 2, 5, 10, 20, 30, and 60 min. For D412A, the 2-min. time point
was omitted due to a limited amount of protein. The time course assay was
repeated in a technical triplicate for all TUT4-N proteins and the standard error
was calculated. The product formation was plotted against time to show the linear
increase of the product formation for the TUT4-N and mutant proteins (Figure
24).
The TUT4-N and mutant proteins are catalytically inefficient, with
approximately 200,000-fold lower enzymatic activity compared to Cid1. Product
formation continued to be linear at 60 min. The TUT4-N protein had a quantified
average final product concentration of 6 ± 0.5 pM. The D412A and N414A
mutants had higher average final product formation of 11 ± 0.1 pM and 19 ± 5
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pM, respectively. On the other hand, the D416A mutant displayed reduced
activity, with a final product formation of 1.5 ± 0.2 pM. Although the activity was
not completely abolished, the product formation of D416A decreased by
approximately 5-fold compared to TUT4-N.
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Figure 24. Product formation of uridylated 15A RNA by TUT4-N proteins.
The product formation of uridylated 15A RNA was quantified at different time
points. The product concentration was plotted over time to compare the increase
in uridylation activity of the TUT4 mutants with TUT4-N. D412A and N414A have
approximately 2-fold and 3-fold increased product formation, respectively, while
D416A has an approximately 5-fold decrease in product formation compared to
TUT4-N. The error represents one standard error.
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3.6.3 Alanine mutation of proposed catalytic residues has little effect on catalytic
activity
Since there was a change in the product formation of uridylated 15A RNA
when comparing TUT4-N to the mutants, the initial velocities of the reactions
were calculated to determine if there is a significant difference in the activity of
the TUT4-N variants. The initial velocities were determined by calculating the
slope of the linear trendline for each protein (Table 3). Although there is an
increase in the initial velocities of D412A and N414A (0.0016 ± 0.00012 pM/sec
and 0.0037 ± 0.0013 pM/sec, respectively) compared to TUT4-N (0.0012 ±
0.00013 pM/sec), there is no significant difference between these mutants and
the WT within error (p-value >0.05). D416A, with an initial velocity of 0.0002 ±
0.00003 pM/sec, is significantly lower than TUT4-N, with a 5-fold decrease in
enzyme activity (p-value=0.009). The difference in initial velocities was plotted on
a bar graph as a visual representation (Figure 25).
Using the initial velocities and concentration of protein, the specific
activities of TUT4-N and the mutants at 0.165 μM UTP was determined. TUT4-N,
with a specific activity of 0.10 ± 0.01 pM/sec/mg, is not significantly different in
activity from the D412A (0.13 ± 0.005 pM/sec/mg) or N414A (0.31 ± 0.12
pM/sec/mg) mutants (p-value >0.05). The D416A mutant, with a specific activity
of 0.02 ± 0.003 pM/sec/mg, is significantly less active than the TUT4-N protein (pvalue= 0.009).
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Table 3. Initial velocities and specific activities of TUT4-N and mutants.
Mutants D412A and N414A do not significantly differ in initial velocity (V0) or
specific activity compared to TUT4-N WT protein (p-value >0.05). D416A is 5-fold
less active than TUT4-N (p-value=0.009).

TUT4-N Construct

V0 (pM/sec)

Specific Activity
(pM/sec/mg)

WT

0.0012 ± 0.00013

0.10 ± 0.01

D412A

0.0016 ± 0.00012

0.13 ± 0.005

N414A

0.0037 ± 0.0013

0.31 ± 0.12

D416A

0.0002 ± 0.00003

0.02 ± 0.003
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0.006

*

0.005

V0 (pM/sec)

0.004
0.003
0.002
0.001
0
WT

D412A

N414A

D416A

Figure 25. Visual representation of difference of initial velocities of TUT4-N
and mutants. D412A and N414A show increased initial velocities compared to
TUT4-N. Within error, there is no significant increase for either mutant (p-value
>0.05). D416A displayed a significant 5-fold decrease in initial velocity compare
to TUT4-N (p-value= 0.009). Initial velocities were determined for each trial and
standard error was calculated. Error bars represent one standard error of
experiments performed in triplicate. Significance is indicated by asterisk (*).
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3.7 TUT7 also displays N-terminal uridylation activity
TUT7, a human homolog believed to be functionally redundant to TUT48,
65, 68, 69, 70

, has a very similar domain layout and shares 40% identity with TUT4.

Similar to TUT4, TUT7 encodes two catalytic regions, one in the C-terminus
believed to be responsible for its catalytic activity, and a second one in the Nterminus, believed to be catalytically inactive. Low conservation between the Nand C- terminus suggest that the duplication of the domains occurred early during
evolution. The N-terminal domains may be less conserved because its catalytic
function is less relevant for its biological function. The N-terminal Ntr domain of
TUT7 is also lacking an identifiable catalytic aspartate triad (Figure 11). Like the
C-terminal Ntr domains of TUT4 and TUT7, the N-terminal domains also share
identity with one another. Because of its similarities to TUT4, we also determined
if the N-terminal region of TUT7 was catalytically active. The N-terminus of TUT7
(amino acids 308 to 476) from human TUT7 (TUT7-N) and the C-terminal
catalytic region (amino acids 1,017 to 1,282) of TUT7 from mouse TUT7 (TUT7C) was cloned and purified by Sarah Lee (4th year Honours student, Heinemann
lab). The human TUT7 plasmid HsCD00082112 from the Harvard PlasmID
Database is lacking the C-terminal Ntr domain. Thus, mouse TUT7 (Addgene
#60044) was used to clone the TUT7-C construct. Considering the impurity of the
TUT7-N protein, I quantified the percentage of TUT7-N in the total protein using
Image Lab. TUT7-N constitutes approximately 10% of the total protein
concentration.

82

Using the purified TUT7 proteins (Figure 26), I performed the radioactive
time course assay experiments on both the N-terminal and C-terminal TUT7
proteins with 15A RNA (Figure 27). For TUT7-N, 12 μg of protein was added to
the reaction at a final concentration of 0.6 mg/mL, the same as in the TUT4-N
activity assays. For TUT7-C, 1 μg of total protein was added at a final
concentration of 0.05 mg/mL. When imaging the time course assay, Whatman
paper with serial dilutions of radiolabelled UTP were spotted to allow for the
quantification of product formation. Technical triplicates were performed for both
proteins and standard error was calculated for each time point. The product
formation was calculated at each time point and plotted over time to visualize the
linear increase of product formation over 60 min. (Figure 28). TUT7-N protein had
a final product formation of 13 ± 0.7 pM after 60 min. (Figure 28A), while for
TUT7-C, 12-fold less enzyme produced a final product formation of 15 ± 3 pM
after 60 min. (Figure 28B). The C-terminal catalytic region of TUT7 is significantly
more active than the N-terminal catalytic region of TUT7.
Initial velocities of TUT7-N and TUT7-C were determined (Table 4). TUT7N, at a concentration 12-fold greater than the TUT7-C protein, had a slightly
lower initial velocity (0.0017 ± 0.0002 pM/sec), within error, compared to the
TUT7-C protein (0.0028 ± 0.0009 pM/sec). When comparing their specific activity
however, TUT7-C has a significantly higher activity (2.8 ± 0.9 pM/sec/mg) than
the TUT7-N protein (0.14 ± 0.01 pM/sec/mg) (Table 5). The TUT7-C protein is
20-fold more active than the TUT7-N protein. Due to the impurity of TUT7-N, the
activity of the N-terminal domains of TUT7 is likely greater than what was
calculated.
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Figure 26. SDS-PAGE of concentrated TUT7-N and TUT7-C proteins. TUT7-N
and TUT7-C (purified by Sarah Lee) were concentrated after purification. The
relative molecular mass of TUT7-N is calculated as 45 kDa, and a band is visible
at that mass, indicated by an arrow. The relative molecular mass of TUT7-C is
calculated as 55 kDa, indicated by an arrow.
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Figure 27. Time course activity of TUT7-N and TUT7-C. A) TUT7-N activity
with 15A RNA over 60 min. B) TUT7-C activity with 15A RNA over 60 min. 15A
RNA (15 nts) is indicated by an arrow.
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Figure 28. Product formation of uridylated 15A RNA by TUT7. The product
formation of uridylated 15A RNA was quantified at different time points for A)
TUT7-N and B) TUT7-C. The product concentration (y-axis) was plotted over
time (x-axis) to visualize the increase in product formation over 60 min. TUT7-N
(12 µg) had a final product concentration of 13 pM while TUT7-C (1 µg) had a
final product concentration of 15 pM with 12-fold less enzyme. Standard error
was calculated for each time point. Error bars represent one standard error.
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Table 4. Initial velocities of TUT7 N- and C-terminal catalytic domains.
TUT7-N with 12-fold more enzyme (12 µg), has an initial velocity (V0) similar to
TUT7-C (1 µg), within error.

Construct

V0 (pM/sec)

TUT7-N (12 µg)

0.0017 ± 0.0002

TUT7-C (1 µg)

0.0028 ± 0.0009

Table 5. Specific activities of TUT7-N and TUT7-C proteins. TUT7-N is
significantly less efficient than TUT7-C (p-value= 0.04).

Construct

Specific Activity
(pM/sec/mg)

TUT7-N

0.14 ± 0.01

TUT7-C

2.8 ± 0.9
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Chapter 4: Discussion
4.1 The TUT4 N-terminal domain is catalytically active
The aim of this study was the characterization of a potential active site in
the N-terminal domain of the human uridylyltransferase TUT4. For
characterization of the N-terminal domains of TUT4 (TUT4-N), I used cloning
techniques, described in Chapter 2, to clone the DNA sequence encoding amino
acids 1 to 678 of TUT4 into a pGEX-6p2 vector with an N-terminal GST tag. Once
the ligation of Tut4-N into the pGEX-6p2 vector was successful, a C-terminal His6
tag was incorporated into the vector between the coding sequence and the stop
codon by site-directed mutagenesis. This construct, termed TUT4-N, was
transformed into BL21 C+ E. coli cells for bacterial expression. TUT4-N protein
expression produced a purified protein yield of 0.19 mg/L; Bacterial expression
less than 1 mg/L is considered low105. This low expression of TUT4-N could be a
result of the mRNA secondary structure. mRNA secondary structure varies
sequence to sequence, which in turn affects the stability of the mRNA106, 107.
mRNA stability influences translation, including the rate, as well as the
expression level of the protein product107. Another possible effect on TUT4
protein expression is codon usage106, 108. BL21 C+ E. coli cells contain a plasmid
encoding 3 tRNAs (R, I, L) that are rare in bacterial cells, to increase protein
expression. The encoded tRNAs that are required for human protein expression
may not be produced at a high enough efficiency in the bacterial cell if the TUT4N protein has a high human codon bias. Faehnle et al. produced recombinant
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mouse TUT4 in insect cells, with yields of 15 mg/mL of concentrated protein32.
Insect cells and expression using the baculovirus expression system, which was
used by Faehnle et al., is capable of producing high amounts of recombinant
proteins with the potential to include protein modifications due to its ability to
efficiently process eukaryotic proteins109. Other members of the polβ family have
been purified in high yields for crystallization. Cid1 purification for crystallization
experiments yielded 5-10 mg/mL of concentrated protein using BL21 DE3 or
BL21 Star E. coli bacterial expression29, 30; Gld2 was purified to a protein
concentration of 8-15 mg/mL for crystallization experiments110. Using different
bacterial cells more suitable for the expression of TUT4-N (e.g. BL21 Star which
increases mRNA stability for increased expression), strains optimized to encode
tRNAs for codons more common in eukaryotic mRNAs, or a eukaryotic
expression system to allow for required eukaryotic translation modifications (e.g.
human or insect cells) could increase TUT4-N protein yield.
TUT4-N was purified using affinity chromatography. After both GST and
Ni-NTA affinity chromatography, the protein was purified to >85%. Two distinct
bands were seen, both containing TUT4-N, verified by western blot. The 105 kDa
protein band corresponds to the full-length TUT4-N protein, while the lower 80
kDa protein band is likely a degradation product due to protein instability.
Cleavage within the protein sequence could be occurring in the linker regions
between the domains. Other members of the polβ family of enzymes have also
shown instability when recombinantly purified, and full-length TUT4 is known to
be difficult to purify32, 111. Purification of other TUTases has resulted in the
presence of other bands after affinity purification. Leishmania tarentolae (L.
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tarentolae) TUTase purification resulted in a single major band, as well as the
presence of 2 minor bands after several affinity, size-exchange, and ion
exchange columns111. Further purification of TUT4-N using ion exchange or sizeexchange chromatography would have resulted in a loss of protein, with the
possibility of further degradation.
During the purification process, it was noticed that TUT4-N protein was
being lost during both GST and Ni-NTA affinity chromatography in the flow
through when the sample was being applied to the column. We speculate that
this is occurring due to misfolding of the protein and aggregation. Aggregation of
misfolded protein could be blocking the GST and His6 tags, preventing binding to
the glutathione and Ni-NTA beads during purification. This could also be
contributing to the low levels of protein being purified. Protein misfolding and
aggregation could be a result of TUT4-N being a partial protein and low stability
of the protein. Also, TUT4 is a protein that has a relatively high cysteine content.
Partially or fully unfolded proteins could have unpaired cysteines, which is
promoting aggregation.
Using the purified TUT4-N protein, radioactive activity assays were used to
elucidate the uridylation activity of the TUT4 N-terminal domains. The purified
enzyme was incubated with RNA substrate and [a-32P]-UTP in an end-point
activity reaction. The N-terminal domains of TUT4 displayed uridylation activity in
vitro. As evident in Figure 16, TUT4-N had uridylation activity when incubated
with 15A RNA (15 nts), an mRNA poly(A) tail mimic, and miR-122 (22 nts), an
miRNA. Although active, 6 µg of TUT4-N protein (0.6 mg/mL) was needed in the
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reaction to see activity after a 30-minute incubation.
To further analyze the activity of TUT4-N, a radioactive time course assay
was performed. TUT4-N had a quantified average final product concentration of 6
± 0.5 pM of uridylated 15A RNA after 60 minutes. The initial velocity of TUT4-N,
determined by the slope of the linear increase of product formation, was
calculated with an activity of 0.0012 ± 0.00013 pM/sec.
Compared to previously published kinetic data of Gld243 and Cid130, it is
evident that TUT4-N is less active than the other Ntr domains containing the
aspartate triad. Gld2, a poly(A) polymerase, had a Vmax of (2.93 ± 0.16) x 10-6
μM/sec with ATP and (24.8 ± 1.17) x 10-6 μM/sec with UTP43. When comparing
these values to the activity of TUT4-N with UTP, the Gld2 enzyme is
approximately 20,000-fold more active than the N-terminal catalytic domains of
TUT4. Although the activity data presented here do not represent a full kinetic
analysis, we can assume that TUT4-N is significantly less active than other
TUTases. Cid130, the yeast homolog, has a catalytic efficiency of 6.6 x 102 M-1
sec-1, while Trypanosoma brucei TUT4112 (TbTUT4) has a catalytic efficiency of
1.5 x 106 M-1 min-1. While the kcat/KM ratios for Cid1 and TbTUT4 cannot be
directly compared to our TUT4-N specific activity113, they give us an indication
that TUT4-N is approximately 108-fold lower in activity.
The activity of TUT4-N may be significantly lower than other homologs due
to it being a partial protein. All of the domains may be required for the N-terminal
catalytic domains to achieve full potential activity. Also, the C-terminal catalytic
domains, when part of the full-length protein, may be the main active region, with
the N-terminal catalytic domains providing a potential secondary binding and
91

modification site for additional substrates. Thus, investigation of the activity of the
N-terminal catalytic region in the context of the full-length protein, e.g. by
mutating the aspartate triad in the C-terminal active site, may result in a more
stable, and potentially more active N-terminal catalytic region. Another potential
reason for the low activity of TUT4-N could be the presence of the 80 kDa
degradation product. This protein is a possible degradation product of TUT4-N,
determined by Western blot. This smaller protein product may partially inhibit the
full-length TUT4-N protein’s ability to catalyze the uridylation of RNA substrate.
From the activity assays, conclusions of processivity cannot be made.
Processive nucleotide addition activity in gel-based assays manifests in a ladderlike product formation. This ladder of nucleotide addition is not observed for
TUT4-N with both 15A RNA or miR-122. Only a single band is visible for both
RNA substrates. From the single band for both miR-122 (approximately 23 nts)
and 15A RNA (approximately 16 nts) we can speculate that TUT4-N
monouridylates its RNA substrates or is only capable of adding a specific, short
poly(U) tail consisting of 2 or 3 uridine residues. The exact number of nucleotides
added will have to be determined by methods that include sequencing, such as
circularized rapid amplification of cDNA ends (cRACE). Full-length TUT4, and
therefore the TUT4 C-terminal catalytic domains, has been shown to
polyuridylate mRNA and pre-miRNA both in vitro and in vivo, leading to
degradation27, 65, 70. In vitro, TUT4 has been shown to have an average poly(U)
tail length of 6 uridine residues after 10 minutes on RNA with a poly(A) tail shorter
than 20 adenine residues65. My data shows that TUT4-N is less processive, with
only 1 or 2 uridine residues being added to 15A RNA, which mimics an mRNA
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poly(A) tail. Monouridylation of mature miRNAs by TUT4 has been shown to
silence miRNA activity67. In the case that a single uridine is being added to miR122 by TUT4-N, TUT4-N could be important in the silencing of miR-122 and
mRNA stability. Without a quantitative answer on poly(U) tail length, TUT4-N
function cannot be concluded. Further studies have to be performed to determine
the number of uridines being added to both miR-122 and 15A RNA.

4.1.1 E. coli cell extracts do not exhibit uridylyltransferase activity.
Due to the presence of contaminating bacterial protein in my TUT4-N
purification, a mock purification was performed using the empty pGEX-6p2 vector
with an inserted C-terminal His6 tag to exclude the possibility that observed
activity was from contaminating E. coli proteins.
GST has a high expression compared to TUT4-N. The Mock protein
yielded purified protein product of a concentration of 7.32 mg/mL. Western blot
analysis using the TUT4-specific antibody verified that there was no TUT4
present in the Mock protein sample.
E. coli itself does not encode any known TUTases, and uridylyltransferase
activity of RNA post-transcriptionally appears limited to eukaryotes8, 25, 41, 57.
Regardless of this, uridylyltransferase activity in eukaryotes was only discovered
a few years ago25, 41, 67, 114, and it cannot be excluded that the annotated
adenylyltransferase PAP1 in E. coli may exhibit residual uridylyltransferase
activity115. Other adenylyltransferases have previously shown nucleotide
promiscuity16, 25, 43, 116, 117. Thus, a mock purification with an empty vector control
was performed identical to the purification of the TUT4 proteins. Figure 18 shows
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that even with high amounts of Mock protein (up to 50 µg), no activity was
observed with 15A RNA or miR-122, confirming that the N-terminal catalytic
region is in fact capable of uridylation activity, and no contaminating bacterial
protein is causing the uridylation activity observed with 15A RNA or miR-122.
Overall, as expected, no uridylyltransferase activity was observed from E.
coli cell extracts after following the mock purification protocol. This data confirms
that the observed TUTase activity stems from the recombinant purified TUT4-N
protein.
4.2 TUT7 N-terminus also shows activity similar to TUT4
Similar to TUT4, the human homolog TUT7 also encodes two potential
active sites32, 73 (Figure 5). Sarah Lee, a 4th year Honours thesis student, purified
the N-terminal catalytic domains of TUT7 (TUT7-N), as well as a construct
containing only the TUT7 C-terminal catalytic domains (TUT7-C). During her
time in the lab, Sarah determined that the TUT7-N protein was also active and
capable of uridylation activity.
Using the TUT7 purified proteins, I performed a time course assay for both
the TUT7-N and TUT7-C proteins to quantify their activity with 15A RNA. The
initial velocities of the N- and C-terminal TUT7 proteins were determined. TUT7-N
protein had an initial velocity of 0.0017 ± 0.0002 pM/sec, while the TUT7-C
protein, with 12-fold less total protein, had an initial velocity of 0.0028 ± 0.0009
pM/sec (Table 4). To compare TUT7-N and TUT7-C, the specific activities of the
enzymes were determined (Table 5). TUT7-N, with a specific activity of 0.14 ±
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0.01 pM/sec/mg, was 20-fold less efficient than TUT7-C, with a specific activity of
2.8 ± 0.9 pM/sec/mg (Figure 29). Through this quantification, it is evident that the
C-terminal catalytic region of TUT7 is significantly more active and efficient at
catalyzing the uridylation of RNA than the N-terminal catalytic region. Again, it
has to be considered that the purified proteins are not full-length proteins, and
that the active sites may exhibit more activity in the context of full-length proteins,
which includes more RNA binding domains, and may be more stable or
catalytically favourable.
The TUT7-N protein had a similar activity to the TUT4-N protein. When
comparing the initial velocities, the activity of TUT4-N, with an initial velocity of
0.0012 ± 0.00013 pM/sec, was not significantly different than the activity of TUT7N, with an initial velocity of 0.0017 ± 0.0002 pM/sec. Comparing the specific
activities of these two enzymes, TUT4-N (0.10 ± 0.01 pM/sec/mg) and TUT7-N
(0.14 ± 0.01 pM/sec/mg) were similar in uridylation efficiency with 15A RNA
substrate (Figure 29). TUT7-N has greater impurities after purification compared
to TUT4-N, with TUT7-N only constituting approximately 10% of the total protein.
Because TUT7-N is under-represented, and the purities of TUT7-N and TUT4-N
differ, TUT7-N could be more active than TUT4-N.
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Figure 29. Specific activities of TUT4-N, TUT7-N, and TUT7-C. TUT4-N (0.10
± 0.01 pM/sec/mg) and TUT7-N (0.14 ± 0.01 pM/sec/mg) have no significant
difference in specific activity. TUT7-C (2.8 ± 0.9 pM/sec/mg) is significantly more
efficient than TUT4-N and TUT7-N (p-value <0.05), denoted by a single asterisk
(*). Error bars represent one standard error.

Due to similarities in activity, the N-terminus of TUT4 and TUT7 may be
similar in their roles. Both TUT4-N and TUT7-N seem to be less active than their
respective C-terminal catalytic regions. This activity could change with substrate
specificity. While TUT7-C is significantly more active than TUT7-N with the
mRNA poly(A) tail mimic 15A RNA, as determined by the specific activity, this
may be substrate specific. The activity of the N-terminal and C-terminal proteins
with other RNAs, such as miR-122, will need to be determined to see if substrate
specificity has an effect on activity. Similar to TUT4-N, TUT7-N and TUT7-C were
less processive than full-length protein, indicating possible monouridylation or low
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processivity polyuridylation (2-3 nts) (Figure 27). This polyuridylation activity
differs from what has been seen for full-length TUT7, which has shown uridylation
addition of greater than 3 nts65.
Compared to other TUTases, all three proteins (TUT4-N, TUT7-N, and
TUT7-C) are less active. Kinetic experiments with TUT1 and U6 snRNA
determined a KM of 55 nM of enzyme to reach half of its maximum velocity, with
more than 1 pmol of uridylated RNA in 8 minutes71. The experiments shown here
required a minimum of 12 μg of TUT4-N and TUT7-N enzyme per time course
reaction (0.6 mg/mL) or 1 μg of TUT7-C per time course reaction (0.05 mg/mL) to
produce pM amounts of uridylated RNA products in 60 minutes. TUT4-N, TUT7N, and TUT7-C are all recombinant partial proteins and may require other
domains from the full-length protein to achieve maximum activity. TUT1 lacking
RNA binding domains has a significant decrease in uridylation activity with less
than 2 fmol of uridylated RNA when 10 nM of enzyme is added71. TUT7-C, which
includes only the C-terminal Ntr and PAP domains, may require the presence of
RNA binding ZnFs for optimal activity, hence why the C-terminal region is less
active than what is expected.
4.3 The N-terminal active site of TUT4 likely exhibits a different active site
compared to the C-terminal domains
The classic active site architecture of nucleotidyltransferases includes
three aspartate residues and two Mg2+ ions13, 31. To identify residues involved in
nucleotidyltransferase activity and Mg2+ coordination in the N-terminal TUT4
domains, I aligned the N- and C-terminal catalytic regions. In the C-terminal Ntr
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domain, residues D1009, D1011, and D1070 form the catalytic triad (Figure 19).
From this alignment, we were unable to identify the aspartates directly aligning to
the catalytic triad in the N-terminal Ntr domain. Four amino acid residues (D412,
N414, D416, and R468) were identified that may be involved in catalysis.
The four proposed residues were mutated to alanine and purified following
the same purification process as the TUT4-N protein. Interestingly, one mutant,
R468A expressed at much lower efficiency compared to other mutants. The
protein yield for this mutant was significantly lower than the other mutants, with
only 0.03 mg/L, compared to a yield of 0.19 mg/L of TUT4-N protein, or 0.12
mg/L, 0.10 mg/L, and 0.19 mg/L yield for D412A, N414A, and D416A,
respectively. A single mutation can have many different effects on a protein,
including folding118, expression, and activity119. In the case of R468A, it is clear
that the single mutation is affecting expression. The arginine residue, protonated
at physiological pH, may be involved in an important interaction with regards to
proper folding. We can assume that the yield of the R468A mutant is low due to
an issue with protein folding, which may lead to degradation. Therefore, due to
low expression and no decrease in end-point activity, we excluded the protein
from the time course assay.
Next, the enzymatic activity of these mutants was tested. Surprisingly, all
four mutants were active with 15A RNA and miR-122, similar to TUT4-N (Figure
22). To further study the effect of these mutations on enzymatic activity, specific
activities were determined for mutants D412A, N414A, and D416A. Compared to
the TUT4-N protein, with an average product formation of 6 ± 0.5 pM of uridylated
15A RNA, the D412A and N414A mutants were more active, with 11 ± 0.1 pM
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and 19 ± 5 pM of uridylated 15A RNA produced, respectively. Interestingly, the
TUT4 D416A mutant produced an average of 1.5 ± 0.2 pM of uridylated 15A RNA
after 60 minutes, which is 5-fold less uridylated RNA than the TUT4-N protein. All
reactions were performed in triplicate and the standard error was calculated for
each TUT4 protein at each time point.
Initial velocity and specific activity for each TUT4-N mutant enzyme was
determined to compare the mutant activity to the TUT4-N activity. TUT4-N had an
initial velocity of 0.0012 ± 0.00013 pM/sec. When comparing the mutants, D412A
and N414A displayed initial velocities of 0.0016 ± 0.00012 pM/sec and 0.0037 ±
0.0013 pM/sec, respectively, while D416A had a 5-fold decrease of activity, with
an initial velocity of 0.0002 ± 0.00003 pM/sec. Within error, the activity of D412A
and N414A were not significantly different than the WT (p-value >0.05) while the
D416A mutant was significantly less active than the TUT4-N protein (pvalue=0.009) (Table 3, Figure 25).
The specific activities of D412A (0.13 ± 0.005 pM/sec/mg) and N414A
(0.31 ± 0.12 pM/sec/mg) were not significantly different (p-value >0.05) in
comparison to the TUT4-N specific activity (0.10 ± 0.01 pM/sec/mg). D416A, with
a specific activity of 0.02 ± 0.003 pM/sec/mg, was significantly less efficient (pvalue= 0.009) than TUT4-N by 5-fold (Table 3, Figure 30).
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Figure 30. Specific activities of TUT4-N and mutants. D412A (0.13 ± 0.005
pM/sec/mg) and N414A (0.31 ± 0.12 pM/sec/mg) mutants did not significantly
differ in activity from TUT4-N, with a specific activity of 0.10 ± 0.01 pM/sec/mg (pvalue >0.05). D416A (0.02 ± 0.003 pM/sec/mg) was 5-fold less efficient than
TUT4-N (p-value=0.009). The significant difference of D416A and TUT4-N is
denoted by a single asterisk (*). Error bars represent one standard error.

With exception of D416A, the N-terminal residues that aligned to the Cterminal catalytic aspartates did not have an effect on the protein activity when
mutated to alanine residues. Consequently, the TUT4 N-terminal region must
take on a different conformational fold compared to the C-terminal domain. Other
aspartate residues, or even glutamates, may be positioned in the active site,
allowing for the catalysis of the nucleotide addition. There may even be only two
residues involved in the N-terminal activity, hence why this catalytic region is less
active than the C-terminal catalytic region. Mutation experiments performed by
Hyde et al. determined that this is possible in the catalytic addition of guanine
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residues to tRNA, catalyzed by tRNAHis guanylyltransferase (Thg1)120. In general,
the first two aspartate residues are required for positioning the metal ions
required for catalysis in the G-specific nucleotidyltransferase Thg1120. Mutation of
the third carboxylate, which is a glutamate in Thg1, only resulted in a slight
decrease in the polymerase activity of human Thg1 compared to the detrimental
decrease in activity when the metal coordinating aspartates were mutated to
alanine residues120. Thg1 can still function, although to a lesser extent, when the
glutamic acid in the active site is mutated120. Thus, it is possible that two
carboxylate residues may be sufficient for catalysis. Further mutational analysis
or crystallization of the N-terminal active site will aid in the identification of the
active site residues in the N-terminal catalytic domain of TUT4.
4.4 TUT4 N-terminal activity shows RNA specificity
As demonstrated in this thesis, the N-terminal domain of TUT4 is
catalytically active. Surprisingly, I found substrate specificity for TUT4-N that has
not been previously described for the full-length protein. Full-length TUT4 is
catalytically active with mRNA65, histone mRNA69, and miRNA42, 64, 66, 67, 68
(Table 1). Interestingly, for the N-terminal domains, no activity is observed with
let-7a or pre-let-7a, known substrates of the full-length TUT4 protein32, 42, 68. This
demonstrates that the N-terminal activity is substrate-specific and may differ from
the substrate specificity of the full-length TUT4 enzyme. For full-length TUT4, it is
believed that the C-terminal CCHC ZnFs are implicated in RNA binding and
possibly specificity73. These ZnFs may be important for RNA binding in relation to
the C-terminal catalytic activity. In vitro, however, the C2H2 ZnF in the N-terminal
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region of TUT4 may also play a role in RNA binding or specificity. Even though
the analyzed TUT4 N-terminal region lacks the C-terminal ZnFs, RNA specificity
and preference for miR-122, but not let-7a, was shown. In other ncPAPs, such as
Cid1 and Gld2, RNA binding is not driven by the presence of ZnFs; Cid1 and
Gld2 only contain two ordered domains, the Ntr and PAP domains25, 43. The
crystal structure of Cid1 revealed a positively charged groove on the protein
surface that is thought to facilitate RNA binding30. It is unknown how RNA
specificity is determined in Cid1 and Gld28, 43, 57, 121, as neither protein displays a
substrate specificity in vitro25, 38, 43, 121. For the N-terminal domain, substrate
specificity must be determined by binding to the active site, yet the exact
mechanism remains to be elucidated.
I have shown in my data that the N-terminal catalytic region was not active
with pre-let-7a and let-7a. The N-terminal catalytic region may thus play a specific
role in e.g. mRNAs or specific miRNA metabolism and may not function in one of
the most prevalent functions of full-length TUT4, the biogenesis of let-7a.
4.5 The purpose of two encoded catalytic regions
The activity of the full-length protein may require the presence, and
therefore catalytic activity, of both the N- and C-terminal catalytic regions. In
2012, Thornton and colleagues tested the catalytic activity of varying TUT4
domains73. Their experiments led to the conclusion that the N-terminal Ntr
domain of TUT4 is inactive73. I here show that the N-terminal domain of TUT4
displays catalytic activity, even though it is low compared to the C-terminal
domain. Interestingly, in the same paper, protein variants lacking any of the N102

terminal domains, or even the second CCHC ZnF in the C-terminus also
displayed no uridylation activity73. Thornton and colleagues concluded that both
N- and C-terminal catalytic regions were required for catalytic activity73. We
conducted our experiments under different conditions, including more domains in
our TUT4-N protein. The inclusion of the entire TUT4 N-terminal region, and not
just the N-terminal Ntr and PAP domains, could be required for uridylation activity
in vitro. The TUT4 (and TUT7) N- and C-terminal regions, although showing
activity in vitro when separated, may be required together to display the full
extent of their activity.
While the biological function of the dual domain architecture of TUT4 and
TUT7 is still unclear, other examples of dual domains have been described in
nature. PAPD1, a mitochondrial adenylyltransferase, forms a dimer necessary for
activity117. Mutation experiments determined that a stable monomer did not have
PAP activity, therefore dimerization was required117. Thg1 is another example of
a nucleotidyltransferase requiring two copies of the catalytic region for activity120.
Thg1 proteins usually exist naturally as a “dimer of dimers” and contain two
copies of the catalytic domains120, 122, 123. Disruption of the interaction between
dimers resulted in a decrease in Thg1 activity120, 124. In some plants, these “dimer
of dimers” have fused, and the protein is now encoded as a tandem of two Thg1
repeats125, 126. TUT4, being a large human protein, may require the two encoded
catalytic regions to fulfill all of its functions in the cell.
Another example are some kinases that contain a catalytically active
pseudokinase domain127, 128. Recently, several pseudokinase domains which
were believed to be inactive, have been shown to indeed exhibit phosphorylation
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activity. In 2011, Daniela Ungureanu and colleagues discovered
autophosphorylation activity in the pseudokinase domain JH2 of human JAK2, a
non-receptor tyrosine kinase127. In the case of HER3, the pseudokinase has low
activity, but dimerizes with and activates the tyrosine kinases HER and HER2128,
129, 130

. The relevance of pseudokinase domain existence is being discovered,

uncovering many biological roles.
Similar to PAPD1 and Thg1, which form dimers, or kinases with two active
domains, such as JAK2 and HER3, TUT4 may require two functional catalytic
regions for uridylation activity. The N-terminal catalytic domains of TUT4 may
also enhance the function of the C-terminal catalytic domains, common in the
dimerized enzymes discussed here.
4.6 Conclusion and Future Directions
Reiterating my hypothesis, I hypothesized that the N-terminal catalytic
region of TUT4 was active and capable of uridylation activity. I here
demonstrated that the TUT4 N-terminal catalytic domains are indeed catalytically
active. When investigating the N-terminal domains of TUT7, uridylation activity
similar to TUT4 is demonstrated.
Not only was TUT4-N catalytically active, the N-terminal domains display
RNA substrate specificity, preferentially uridylating miR-122 and 15A RNA.
Interestingly, no activity was observed with let-7a or pre-let-7a, which are known
substrates of the full-length TUT4 protein. This implies that the TUT4 N-terminal
domains may play a role in pathways other than the well-studied let-7a
biogenesis pathway.
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Mutation of the putative active site residues to alanine residues
demonstrated no significant change in the activity of the TUT4 N-terminal
domains, with the exception of D416A, which led to a significant decrease in
activity. Thus, residue D416 likely plays a role in catalysis. These data indicate
that the TUT4 N-terminal region may fold differently than the C-terminus. Further
experiments, such as mutational analysis or a crystal structure, will elucidate
which residues are involved in catalyzing the addition of uridines onto the RNA
substrate.
Although TUT4-N is capable of uridylating specific RNA substrates, it
would be interesting to investigate the nucleotide preference of TUT4-N. In the Cterminus, a histidine residue in the PAP domain preferentially allows UTP into the
active site, by recognizing the O4 carbonyl of the uridine base as well as
sterically hindering ATP from entering the active site30. This amino acid is
conserved in all true TUTases yet seems to be lacking in the N-terminal PAP
domain of TUT4. Without the histidine residue, the TUT4 N-terminal catalytic
domains, while active with UTP, may give preference to different nucleotide
addition in vivo, including ATP. Nucleotide competition experiments and a
detailed kinetic characterization will determine the NTP preference of the TUT4
N-terminus. This will elucidate other possible functions of the N-terminus of
TUT4, especially for possible splicing variants which lack C-terminal domains.
Overall, the experimental results presented in this work are just the
beginning of the characterization of the N-terminal domains of TUT4. The next
steps to elucidate the biological functions of this activity will expand our
knowledge on TUTases as a family of enzymes. The substrate specificity, and
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therefore the pathways that TUT4 regulates, could be much more expansive than
we originally presumed. Exploring the function of the TUT4 N-terminus could give
valuable insight into other important functions of TUT4 that have yet to be
elucidated.
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